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Near-perfect adherence to antiretroviral therapy (ART) is necessary to prevent treatment 
failure and resistance. In children, protease-inhibitor (PI)-based regimens appear more potent 
than non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens, but poor PI taste 
and tolerability may lead to worse adherence. We aimed to disentangle relationships among ART 
regimen, adherence, and viral control. 
In Aim 1, we assessed treatment-naïve children for differences in time to treatment 
disruption across randomly assigned PI versus NNRTI-based initial ART. At 4 years, the hazard 
ratio (HR) for treatment disruptions on PI versus NNRTI-based regimens was 1.19 (95% 
confidence interval [CI] 0.88-1.61). By study end, treatment disruption probabilities converged 
with HR 1.11 (95% CI 0.84-1.48). Reported reasons for treatment disruptions suggested that PI 
participants experienced greater tolerability problems. 
In Aim 2, we estimated the per-protocol effect of initial PI versus NNRTI-based ART on 
time to treatment failure in children with HIV in a setting of ideal adherence. After an intention-
to-treat (ITT) analysis, we generated per-protocol estimates by administratively right-censoring 
participants experiencing protocol deviations (non-medically indicated treatment disruption or 
dropout) and using inverse-probability of censoring weights to correct for imparted informative 
censoring. In ITT analysis, PI participants experienced 4-year treatment failure probabilities of 
41.3% versus 39.5% (NNRTIs), risk difference (RD) 1.8%, HR 1.09 (95% CI 0.74-1.60). In per-
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protocol analysis, PI participants experienced treatment failure probabilities of 35.5% versus 
29.5% (NNRTI), RD 6.4%, HR 1.30 (95% CI 0.80-2.12). Protocol deviations were non-
differential across arms. Shifts in failure probabilities from the ITT to per-protocol analysis were 
5.7% (PI) versus 10.3% (NNRTI).  
In conclusion, children experienced similar time to treatment disruption for initial PI- and 
NNRTI-based ART, despite greater PI tolerability problems. With ideal adherence, NNRTIs 
appeared more potent, but PIs appeared more robust against non-adherence. Principal drivers of 
the observed parent study null effects were not non-adherence, but rather regimen potency and 
robustness. Shifts in ITT to per-protocol estimates yield a novel method of quantifying regimen 
robustness. We conclude that regimen potency and robustness, in addition to traditional 
components (e.g., adherence), provide a more detailed framework for the various elements 
contributing to the composite outcome of treatment efficacy. 
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CHAPTER 1: INTRODUCTION 
A. The Burden of HIV in Pediatric Populations 
Pediatric HIV-related mortality is high, but mortality is decreasing with widespread 
antiretroviral therapy (ART). Globally, 1.8 million children under age 15 years are living with 
HIV.1 This number continues to increase due to better survival and approximately 180,000 newly 
infected children each year. Untreated, mortality by age 18 months in HIV-infected children is as 
high as 51%.2 Although ART has improved pediatric HIV long-term survival,3 HIV/AIDS still 
kills 110,000 children annually.1 To attain maximum and sustained decreases in pediatric HIV 
mortality, we must optimize pediatric ART.   
B. Infants, Children, and Adolescents with HIV are Vulnerable Populations 
Infants, children, and adolescents suffer greater consequences from ART treatment 
failure. First, due to a lack of studies, greater variability in drug absorption and 
pharmacokinetics, and age-related changes, children have fewer licensed antiretroviral drugs.4,5 
Even some licensed drugs are becoming more limited in utility, as antiretroviral use in 
prevention of mother-to-child transmission (PMTCT) of HIV has selected for antiretroviral 
resistance.6-14  
Second, long-term toxicity and tolerability have greater implications in children.15 
Pediatric populations must face longer potential treatment duration, as therapy started during 
infancy may lead to drug exposure on the order of 70 years. Due to greater cumulative drug 
exposure and potential impact on growth, children are more vulnerable than adults to metabolic 
side effects of therapy, including lipodystrophy, dyslipidemia, insulin resistance, 
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hyperlactactemia, osteopenia, and growth failure.16,17 Greater cumulative drug exposure is also 
associated with increased cardiovascular risk, which may be a potential long-term complication 
as children progress into adulthood.16 Progression to secondary or salvage regimens typically 
means more toxic regimens. Both drug toxicity and intolerance, especially poor palatability, have 
compromised pediatric ART adherence.18-20  
Third, ART appears to be less successful in producing viral suppression in children,21 
who may require more potent regimens to achieve viral suppression.5 Adolescents have 
particularly worse viral and immunological outcomes due to poor ART adherence.22-25  
Finally, children are more prone to acquisition of antiretroviral resistance mutations due 
to: (1) higher plasma viral loads, allowing more spontaneous mutations; (2) less robust antiviral 
immune responses; (3) pharmacokinetic challenges with concomitant requirements for more 
frequent dosing; and (4) social and behavioral dependency.5  
Thus, treatment failure has great consequences in children.  
C. The Critical Role of Adherence to ART 
Although HIV viral replication can be suppressed by ART, virions arise from multiple 
compartments.26 Unfortunately, HIV establishes a stable form of latency as integrated provirus in 
resting memory T cells and macrophages.27,28 While only a small fraction (<0.05%) of resting 
CD4+ T cell population in the circulation or lymph nodes carries integrated HIV-1 DNA and 
only an even smaller fraction are replication-competent, the estimated total body number of 
resting CD4+ T cells with integrated HIV-1 DNA ranges from 4.6 x 107 to 3.4 x 107 cells.28 Even 
with prolonged suppression of plasma viremia on ART, replication-competent virus can be 
routinely recovered from resting CD4+ T cells,29,30 and infrequent detection of new drug 
resistance mutations provide evidence for viral latency rather than drug failure.30 As memory 
CD4+ T cells survive for months to years,31 ART must sustain viral suppression indefinitely or 
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risk rebound of viral replication. 
Optimal and sustained outcomes are strongly associated with the degree of treatment 
adherence.22,23,32,33 The sentinel data in adults found that a mere 10% decrease in adherence was 
associated with a doubling of HIV RNA viral load.32,34 Paterson et. al. were the first to 
demonstrate the minimal room for error in adherence. In HIV-infected adults, 99 patients were 
prescribed HAART with an unboosted protease inhibitor and followed for a median of 6 months 
(range, 3 to 15 months) using adherence measured by a Medication Event Monitoring System 
(MEMS). At their last study visit, patients with ≥95% adherence had the lowest proportion of 
viral failure (viral load >400 copies/mL; Figure 1.1). Even slightly worse adherence at 90 to 
94.9% increased viral failure by 33%. Subjects with ≥95% adherence also had better CD4+ 
lymphocyte counts, fewer days in the hospital, and no new opportunistic infections or deaths.33  
The adherence effect on decreasing viral load also decreases the probability of HIV sub-
populations acquiring antiretroviral resistance mutations,5,35 preserving the longevity of current 
and future ART regimens. Unfortunately, initial studies of adult ART adherence using objective 
measures estimated average adherence around 70%,36-39 especially among those who failed to 





Figure 1.1. Relationship between adherence to ART and viral failure. From Annals of 
Internal Medicine, Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor 
therapy and outcomes in patients with HIV infection, Vol. 133, Issue 1, Page 24. Copyright © 
2000 American College of Physicians. All Rights Reserved. Reprinted with the permission of 





D. Drug-Adherence Relationships in Children  
Choice of antiretroviral drugs may affect adherence. Drug characteristics can make 
pediatric adherence more difficult.19,20,41-44 The greatest contrast in commonly used pediatric 
drugs is between non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors 
(PI).  
PIs have higher drug toxicity, especially gastrointestinal side effects, and intolerance, 
 
5 
particularly their noxious taste.18-20 Although a highly potent PI, lopinavir with boosting doses of 
ritonavir (LPV/r), has better viral suppression than NNRTIs,41 a recent clinical trial failed to 
identify better treatment success in children randomized to PIs than NNRTIs45—perhaps due to 
differences in adherence.  
Antiretroviral drugs also differ in packaging, such as availability in liquid or pill 
formulations.46,47 Even when children are able to swallow pills, certain protease inhibitors are 
only available as large pills, complicating swallowing for children. No protease inhibitors are 
available as complete-regimen combinations, whereas combined drugs with NNRTIs can 
facilitate adherence through administration of fewer pills.4  
Increased dosing frequency has been associated with worse adherence,18,48-50 whereas 
some NNRTIs, most notably efavirenz, have more suitable pharmacokinetics for once daily 
dosing administration. Thus, NNRTIs offer many adherence advantages of PIs.  
Buscher et. al. performed a prospective observational cohort study of 99 ART-naïve 
patients, comparing ART regimen and dosing frequency using a visual analogue scale to measure 
adherence. Participants taking once-daily regimens had modestly higher adherence (99.5%), 
compared to twice-daily regimens (94% adherence). However, once daily fixed dose 
combinations (100% adherence) were similar to regimens of two or more pills (99.3% 
adherence). Thus, dose frequency but not pill burden was associated with adherence.51  
However, in a Maggiolo et. al. study of adults, both dose frequency and pill burden were 
associated with adherence. In this study, NNRTI-based therapy was more acceptable than PI-
based therapy.52 
E. Adherence-Response Relationships Differ by Drug Class 
Although these early studies first defined minimum ART adherence targets for unboosted 
PI regimens, subsequent studies suggested that adherence targets should vary by drug class. 
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Much of these subsequent data have focused on the relationship between adherence and drug 
resistance—related to drug potency, viral fitness, adherence patterns, and 
pharmacogenomics.53,54  
Bangsberg et. al. evaluated the prevalence of resistance by adherence levels in patients 
treated with NNRTIs or unboosted PIs, using unannounced pill count measures for adherence, 
viral load monitoring, genotypic resistance testing, and single-cycle recombinant phenotypic 
susceptibility assays to test replication capacity. NNRTI-based regimens were associated with 
better viral suppression to <50 copies/mL, but in patients failing to suppress, NNRTI regimens 
also had more frequent resistance, which was related to viral fitness. At 0-48% adherence, 69% 
of the NNRTI group had resistance, while 23% of the PI group had resistance (Figure 1.2).55  
Another study by Bangsberg found similar results in a cohort of 110 participants on 
NNRTI or unboosted PI therapy. Participants were followed for a median 9.1 months with 
monthly adherence measurements by unannounced pill counts or MEMS and monthly viral load 
measurements. The majority of NNRTI-treated participants were suppressed to <400 copies/mL 
at adherence 54-100%, which was much more common than unboosted PI-treated participants, 





Figure 1.2. Prevalence of viral suppression, viral failure without resistance, and viral 
failure with resistance by adherence quartile and drug regimen. (a) Patients treated with 
non-nucleoside reverse transcriptase inhibitor; (b) patients treated with protease inhibitor. 
Reprinted from Bangsberg DR, Acosta EP, Gupta R, et al., Adherence-resistance relationships 
for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness, 
AIDS, Vol. 20, Issue 2, Page 227, Copyright © 2006 Lippincott Williams & Wilkins, with 




Maggiolo et. al.’s cross-sectional study of 543 patients had more viral suppression in 
patients receiving NNRTI-based ART over PI-based ART at similar levels of adherence, as 
measured by an adherence questionnaire.52 Better viral suppression was noted primarily at 
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adherence of 75-95%. This study compared NNRTIs to grouped data on patients receiving 
boosted or unboosted PI regimens. However, participants had different levels of treatment 
experience and regimens spanned first line therapy to salvage therapy.  
A subsequent study by Maggiolo et. al. of a cohort including 1,133 participants on stable 
NNRTI or PI ART compared NNRTI ART to separate categories of unboosted and boosted PI 
ART. NNRTI ART had more viral suppression than either PI group at adherence <95%.56  
In contrast, some adult and pediatric data indicate that boosted PIs are more forgiving of 
suboptimal adherence than unboosted PIs or NNRTIs.57-59 Similarly, a cohort study of 78 
children in South Africa compared a boosted PI (ritonavir-boosted lopinavir) with unboosted PI 
and NNRTI ART.60 Adherence was measured by MEMS, and viral loads were measured every 6 
months. Children who were receiving PI-based regimens had more viral suppression, even with 
poor treatment adherence. Notably, the majority of patients were exposed to single-dose 
nevirapine for PMTCT, which may have predisposed these children to higher risk of NNRTI 
failure, and ten children were on second-line therapy.  
A major randomized pediatric trial comparing PI-based to NNRTI-based ART in 
treatment-naïve children without single-dose nevirapine exposure is the PENPACT-1 (PENTA 
9/PACTG 390) study. This study identified no significant differences in viral failure by treatment 
regimen.45 The adherence analysis of PENPACT-1 is the subject of this proposal. 
F. Measuring Adherence and Treatment Disruptions 
The PENPACT-1 trial measured adherence using the Pediatric AIDS Clinical Trials 
Group (PACTG) adherence questionnaires (Appendices 1 and 2). The PACTG adherence 
questionnaires were first validated by Van Dyke et. al.61 The validation study was performed in a 
cohort of 193 children aged 4 months to 17 years in a 4-arm study including various 3- or 4-drug 
combinations of stavudine, lamivudine, nevirapine, ritonavir, and nelfinavir enrolled between 
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December 1997 and September 1998. Questionnaires were administered every 3 months and 
relied on the number of doses of each medication missed during the 3 days preceding the study 
visit. Responses were categorized into full adherence and non-full adherence, defined as missing 
no doses and missing at least one dose, respectively. Seventy percent of children reported full 
adherence, and 30% of children reported non-full adherence. Adherence was reported as 68% for 
nelfinavir but about 80% for all other drugs. Challenges to adherence were reported most 
frequently for ritonavir and nelfinavir, including poor taste, patient refusal, and scheduling 
problems. Adherence was associated with viral response. Full adherence was reported in 92% of 
children with a ≥2 log10 drop in viral load, but full adherence was reported in only 64% of 
children with <2 log10 drop in viral load. 
Unfortunately, adherence questionnaires cannot capture all aspects of adherence. Not 
only are questionnaires prone to measurement error in self-reporting, but they may not capture 
patterns of adherence. Patterns of missed doses may have differential effects on viral control. For 
boosted protease inhibitors, average adherence is the primary predictor of viral suppression. 
Parenti et. al. evaluated two cohorts with a total of 72 patients who were prescribed ritonavir-
boosted PI regimens and compared patterns of missed doses. Average adherence was a stronger 
predictor of viral suppression than duration or frequency of treatment interruptions.62 In contrast 
for NNRTIs, a cohort study of 71 adult patients on nevirapine- or efavirenz-based ART 
identified repeated unplanned treatment interruption of ≥48 hours as an independent predictor of 
viral failure and resistance to the NNRTI class.63       
G. Moving from Adherence to Treatment Disruptions and Protocol Deviations 
 More recent advances in the analysis of pragmatic clinical trials have moved from 
traditional adherence analyses to estimating per-protocol effect estimates.64 These per-protocol 
effect estimates generate estimates that represent treatment effectiveness when the treatment is 
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used as indicated by the protocol, i.e. what would have been observed if all patients had adhered 
to the trial protocol. The result is an estimate that adjusts for post-randomization factors, 
including confounding bias due to incomplete adherence or use of off-protocol concomitant 
therapies and selection bias due to differential loss to follow-up. 
 In general, these per-protocol estimates of pragmatic trials have relied on censoring 
participants for non-medically indicated reasons, censoring when it is no longer certain that 
participants are receiving treatment, and adjusting for bias due to incomplete adherence. Thus, of 
interest is no longer merely adherence to a specific prescription, but rather adherence to a 
protocol, which may allow some tolerance for non-adherence.  
 This method overcomes historical challenges to per-protocol analyses. The primary 
origin of objections to traditional per-protocol analyses have been the results of the Coronary 
Drug Project. In this study, the original per-protocol analysis generated a 9.4% risk difference in 
5-year mortality between adherers and non-adherers to placebo.65 Although this original analysis 
generated skepticism on the validity of traditional per-protocol analyses, developments in 
analytical methods since that time, such as g-methods, have generated more plausible risk 
differences of 2.5%, ranging from -0.7% to 4.5%, using the more recent per-protocol methods, 
thereby supporting the validity of this approach.66,67 Such methods have also been applied to 
adult ART initiation studies, substantiating the increasing acceptance of this approach.68,69 
 As a result, estimating adherence to a protocol is now the more relevant analytical 
approach and comprises a composite of traditional adherence measures, use of off-protocol 
medications, and loss to follow-up. Such a definition of protocol adherence may be more aptly 
called treatment disruptions or protocol deviations. As a result, below we refer to protocol 
adherence and refer to violations of protocol adherence as either treatment disruptions or 
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protocol deviations, thereby making “non-adherence”, “treatment disruptions”, and “protocol 
deviations” generally interchangeable terms that will be used throughout the remainder of this 
document. 
H. Critical Review of the Literature 
To date, publications discussing drug-related factors on adherence have strong 
limitations. First, no pediatric drug-specific adherence studies have randomized patients to their 
comparison drug regimens, leaving potential unmeasured confounding, including confounding 
by indication. Second, most studies have been cross-sectional, failing to account for changes in 
adherence over time and generating prevalent associations, rather than incident associations. 
Third, these studies fail to account for the cyclical relationship between adherence and viral 
control, namely that adherence affects viral control, which affects interventions taken to address 
adherence. Fourth, most studies have been restricted in their size and distribution of their study 
populations, often taking place at one or a few centers in one country, thus potentially limiting 
their generalizability. Fifth, many studies do not account for the measurement error in their 
adherence assessments, which can vary greatly according to the measurement method19,70-73: 
physician perception,71,74 self-report or caregiver report,24,46,71,73,75,76 structured 
questionnaires,19,72 pharmacy refill data,19,70,71 appointments kept,70,71 medication measurement 
systems (e.g. pill counts, visual analogue scales for syrups),71,73,77 medication event monitoring 
systems,78-81 or therapeutic drug monitoring.82,83 Finally, few studies have accounted for protocol 
non-adherence by applying more recent developments in estimating the per-protocol effect.84 
These study deficiencies limit the ability to generate inferences regarding relationships among 




CHAPTER 2: STATEMENT OF SPECIFIC AIMS 
A. Overview 
For HIV-infected children, optimal survival outcomes can only be achieved with near-
perfect antiretroviral therapy (ART) adherence. Adherence lapses result in treatment failure and 
acquisition of resistance mutations, which are particularly consequential in children: Compared 
with adults, children have fewer available licensed drugs; greater pharmacokinetic variability; 
more potential for toxicity from longer lifetime drug exposure; greater social vulnerability; and 
more rapid progression to HIV disease and death.20,43,47,50,85-87 Poor adherence may also 
jeopardize the validity of studies that estimate the outcomes of different treatment regimens.88 
Few pediatric studies have evaluated longitudinal relationships among ART regimens, 
adherence, and viral control. These relationships become entangled in clinical trials comparing 
different ART regimens, potentially biasing results. Therefore, applying causal inference 
methods may disentangle relationships among ART regimen, adherence, and viral control, 
allowing (1) identification of ART regimens that pose greater adherence challenges and (2) more 
valid estimation of ART treatment efficacy with good adherence.  
Unfortunately, prior pediatric studies on the ART regimens, adherence, and viral control 
have methodological limitations. First, no prior pediatric adherence studies have used data on 
children that underwent randomized allocation; thereby leaving these studies open to residual 
confounding from unmeasured covariates. Secondly, pediatric studies on the relationship 
between ART regimen and viral control have failed to account for the time-varying nature of 
adherence, limiting analyses to either cross-sectional designs or intent-to-treat analyses. These 
 
13 
shortcomings limit the ability to generate inferences about relationships among ART regimen, 
adherence, and viral control. 
In the PENPACT-1 study, 266 HIV-1-infected, treatment-naïve children from Europe, 
North America, and South America were randomized to ART with either a PI or NNRTI.45 No 
significant differences were identified in viral control over 4 years of ART. We suspect that these 
results may be explained by opposing effects of adherence and regimen potency. 
Our overarching hypothesis is that in HIV-infected children initiating ART, PI-based 
therapy (vs. NNRTI-based therapy) will have worse adherence that is compensated by better 
viral control. 
B. Aim 1  
We aim to assess PENPACT-1 participants for differences in time to first treatment 
disruption across randomized PI vs. NNRTI treatment arms at 4 years and end of study. Using 
existing data on 266 HIV-1-infected, ART-naïve children randomized to initial ART with a PI or 
NNRTI, we will compare time to treatment disruption longitudinally over 4 years and end of 
study, derived from ART regimen stops or switches on treatment records and 24-weekly 
questionnaires of reported missed doses within 3 days of clinic visit. We will further explore 
reasons for missed doses by documented reasons for treatment stops or switches and reported 
reasons for missed doses within 14 days of clinic visit as reported on adherence questionnaires. 
We will use Kaplan-Meier estimators and Cox proportional hazards models to estimate the risk 
of treatment disruption at 4 years after randomization and at the end of study (i.e., 6 years).  
Hypothesis: We hypothesize that participants receiving initial PI-based ART will report 
worse adherence. We further hypothesize that reasons for treatment disruption will demonstrate 
worse tolerability for PI regimens. 
Rationale: To optimize clinical outcomes, clinicians must consider both drug 
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pharmacology and adherence to ART regimen. In children, the poor taste and gastrointestinal 
toxicity of PIs may lead to worse adherence.18-20,41-43 Even if children are able to swallow pills, 
certain PIs are available only as large pills.89 No PIs are available as complete-regimen 
combinations for children, whereas single-tablet NNRTI regimens can facilitate adherence 
through administration of fewer pills.4,90-93 Higher dosing frequency has also been associated 
with more frequent treatment disruptions.48,51,90,92  Some NNRTIs, most notably efavirenz, have 
more suitable pharmacokinetics for once daily administration, whereas most PI-based regimens 
are administered at least twice daily.94 In sum, the noxious taste, worse toxicity and tolerability, 
unavailability of single-tablet regimen, and more frequent administration requirements of PIs 
found our hypothesis of worse expected adherence in the PI arm. 
C. Aim 2 
We aim to estimate the per-protocol effect of initial PI versus NNRTI-based ART on time 
to treatment failure in treatment-naïve children living with HIV in developed countries in a 
setting of ideal adherence. First, we will generate time to treatment disruption under 
conventional intention-to-treat (ITT) analysis. Then, we will use Robins-Finkelstein inverse 
probability-of-censoring weights to correct for differences in protocol non-adherence by PI vs. 
NNRTI regimen.88,95 Adherence correction will allow estimation of viral control by PI vs. 
NNRTI regimen under conditions of good adherence throughout the 4-year follow-up period. We 
will then compare the shift in ITT to per-protocol estimates of PI vs. NNRTI initial regimens on 
time to viral failure.  
Hypothesis: We hypothesize that with good adherence, PI regimens will have better viral 
control. We hypothesize that under the ITT analysis allowing post-randomization protocol 
deviations, initial PI and NNRTI-based ART will have similar time to viral control. We further 
hypothesize that under optimal adherence, initial PI therapy will be more robust against protocol 
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deviations, with less of a shift in ITT versus per-protocol estimates in time to viral failure. 
 Rationale: The ITT parameter estimates the effect of being assigned to a treatment 
protocol. In standard ITT analysis of clinical trials, poor adherence typically biases estimates of 
effective treatments towards the null, resulting in under-estimation of treatment efficacy and 
over-estimation of treatment safety and tolerability. The per-protocol parameter estimates the 
effect of being assigned to, and remaining on, a treatment protocol. The Robins-Finkelstein (RF) 
inverse-probability of censoring weights (IPCW) method of per-protocol analysis provides a 
principled way to address problematic post-randomization protocol violations, such as poor 
adherence and study dropout, which may affect clinical trial results.95 
 In PENPACT-1, we suspect that the null result of the ITT analysis may have resulted 
from a cancellation effect: Worse adherence to PIs cancelled their more robust viral efficacy. As 
described in Aim 1 above, we hypothesize that PI regimens will have worse adherence than 
NNRTI regimens. However, in Aim 2 we suspect that PIs will be more robust against protocol 
deviations. Boosted PI-based regimens appear more forgiving of treatment disruptions than 
NNRTI-based regimens.60,96-98 In a pediatric trial comparing continuing a boosted PI regimen to 
switching to an NNRTI, inadequate adherence had less influence on viral outcomes in the 
boosted PI arm.99 Another pediatric trial of a boosted PI versus NNRTI regimen found greater 
viral efficacy for the boosted PI.100 Thus, we expect that PIs will be more robust against protocol 
deviations in this study, thereby cancelling any identified non-adherence effects. 
D. Conclusion 
By combining these two aims, we plan to disentagle effects of pediatric ART regimens 
and adherence on HIV viral control, thereby allowing clinicians to consider optimal regimens 
that affect both adherence and viral control. 
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CHAPTER 3: METHODS 
A. Overview 
We plan to disentangle relationships among drug regimen, protocol non-adherence, and 
HIV viral control in HIV-infected pediatric populations—a population with high risk for high 
mortality and long-term consequences of treatment failure. Disentangling these relationships will 
occur via two steps presented in two aims. In Aim 1, we will first estimate differences in 
treatment disruption between randomized protease inhibitor (PI) versus non-nucleoside reverse 
transcriptase inhibitor (NNRTI) ART regimens. In Aim 2, we will estimate viral suppression by 
ART regimen under traditional ITT analysis, then under a per-protocol analysis accounting for 
protocol deviation. This result will illustrate the shift in effect estimates when allowing protocol 
deviations (ITT analysis) and when correcting for protocol non-adherence (per-protocol 
analysis). With increased knowledge about the inter-relationships among drug regimen, protocol 
adherence, and viral control, clinicians would be able to make more informed decisions about 
ART regimens to use in infants, children, and adolescents, including patients at high risk for poor 
ART adherence.   
 The methods we will apply will help overcome common limitations in the published 
literature by implementing the following novel elements:  
• One of the first randomized controlled trial on pediatric drug regimen adherence: Most 
prior work on drug-related pediatric ART adherence has been observational, allowing for 
possible unmeasured confounding, which would be mitigated by treatment 
randomization.   
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• Collaboration of two international pediatric HIV research networks: This proposed work 
is the first collaboration between the two major international pediatric HIV clinical trials 
groups: Pediatric AIDS Clinical Trials Group (PACTG)—renamed International 
Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)—and Paediatric 
European Network for Treatment of AIDS (PENTA).  This collaboration results in a 
broadly representative study population, involving 68 study sites in 13 countries in North 
America, South America, and Europe. 
• Longitudinal analysis of adherence and viral control: We will perform longitudinal 
analysis of relationships among PI versus NNRTI regimen, protocol adherence, and viral 
control over 4 years. We will assess the changing adherence patterns over time and how 
adherence relates to changing viral control over time. This approach will allow 
disentagling of cyclical relationships among time-varying adherence, which leads to 
changes in viral control, which leads to interventions to improve adherence, which again 
affects adherence.   
These methodological elements relate to study design, study population, and statistical 
analysis. Study design and population will be discussed in Section B as context for both Aim 1 
and Aim 2. Statistical methods will differ by aim and are described separately for Aim 1 (Section 
C) or Aim 2 (Section D).  
B. Study Design and Population 
B1. Overview of Study Design 
We will analyze data collected from PENPACT-1 (PACTG 390 / PENTA 9), an 
international multicenter phase 2/3, randomized, open-label trial enrolling children infected with 
HIV-1 from 68 clinical centers in Europe and North and South America between September 25, 
2002, and September 7, 2005.45 At entry, children were simultaneously assigned (1:1): (a) to start 
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ART with two nucleoside reverse transcriptase inhibitors (NRTI) plus either a PI or an NNRTI 
and also (b) to switch from first-line to second-line ART at viral-load thresholds of either 1,000 
copies/mL or 30,000 copies/mL. The treating clinician chose the two NRTI drugs combined with 
a drug from the randomly assigned PI or NNRTI class.  
Children underwent clinical and HIV-1 RNA viral load assessments at randomization 
(week 0), weeks 2, 4, 8, 12, 16, 24, and then every 12 weeks until the last child assigned to 
treatment reached 4 years of follow-up (August 31, 2009). Treatment starts, changes, and 
stoppages were recorded at clinical visits and ad hoc throughout the study, along with reasons for 
the medication change. Trained study personnel administered validated adherence questionnaires 
every 24 weeks after randomization. Adherence questionnaires recorded the number of missed 
doses to all antiretrovirals over the 3 days prior to visit and barriers to adherence experienced 
within 2 weeks prior to visit. 
Aim 1 will compare PI versus NNRTI treatment arms longitudinally over 4 years and end 
of study for differences in time to treatment disruption, as measured by study treatment records 
and 24-weekly adherence questionnaires. Aim 2 will estimate the effect of initial PI versus 
NNRTI ART on time to treatment failure under a traditional ITT analysis, then under a per-
protocol analysis correcting for protocol non-adherence over 4 years. 
B2. Study Population  
The study population will include the 263 participants (of 266 randomized) from the ITT 
analysis of PENPACT-1. Eligible children were >30 days and <18 years of age with a confirmed 
age-appropriate HIV laboratory diagnosis on two separate positive peripheral blood specimens 
from different days. The subject had to be antiretroviral-naïve or have received less than 56 
consecutive days after birth of antiviral drugs used to prevent mother-to-infant transmission of 
HIV.   
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Participants were excluded from PENPACT-1 if the participant had any of the following: 
infant or maternal peripartum exposure to nevirapine for prevention of mother-to-child HIV 
transmission; current grade 3 or 4 clinical or laboratory toxicity; an active opportunistic infection 
and/or serious bacterial infection at study entry; contraindications to receiving the trial therapies; 
receipt of any cytotoxic therapy for malignancy; pregnancy or breastfeeding. 
The characteristics of PENPACT-1’s ITT study population are listed in Table 3.1. After 
excluding three participants who did not start ART, a total of 263 were included from the 
following countries: United States 75, Germany 21, Spain 2, France 17, Italy 22, Romania 31, 
Brazil 41, United Kingdom 37, Austria 2, Bahamas 4, and Argentina 11. We expect this study 
population to be representative of newly diagnosed HIV-infected children receiving care at HIV 




Table 3.1. Baseline characteristics of participants in the modified intention-to-treat analysis 
of PENPACT-1. 
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; N, total sample size; n, subsample size; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. 
a PENTA sites were predominantly in Europe, South America, and the Bahamas. PACTG/IMPAACT sites were 
based primarily in the United States. 
b Not all patients had successful baseline genotypic resistance assays.  
  
  Randomized Group 
Variable  PI NNRTI Total 
N  131 132 263 
Age  
  <3 years       
  3-17 years           
















6.5 (2.8, 12.9) 
Sex 










  Black, Non-Hispanic     
  White, Non-Hispanic    


















  PENTA                   













Route of Infection 
  Vertical 













CDC Clinical Stage 
  N 
  A                    
  B 





















Weight-for-Age Z-score Median (IQR) -0.5 (-1.6, 0.1) -0.7 (-1.6, 0.2) -0.6 (-1.6, 0.1) 
Height-for-Age Z-score Median (IQR) -0.9 (-1.5, -0.2) -0.9 (-1.8, 0) -0.9 (-1.7, -0.2) 
CD4 Z score Median (IQR) -3.6 (-7.2, -1.7) -3.4 (-6.5, -1.4) -3.5 (-6.8, -1.6) 
Viral Load log10 copies/mL Median (IQR) 5.1 (4.5, 5.7) 5.0 (4.5, 5.6) 5.0 (4.5, 5.7) 
Perinatal ART Exposure n (%) 19 (15%) 20 (15%) 39 (15%) 
≥1 Major Resistance Mutationb n/N (%) 5/116 (4%) 5/123 (4%) 10/239 (4%) 
HIV-1 subtype 
  B 
  C 
  F 
  A/CRF_AG/D/G 


























  1,000 copies/mL    















B3. Parent Study Results 
In PENPACT-1, 234 of 263 (89%) of enrollees were in follow-up at 4 years, the primary 
endpoint. The results of the parent study found little difference between PIs and NNRTIS in (a) 
mean changes in viral load from baseline to 4 years, which were -3.31 log10 copies/mL for 
protease inhibitors versus -3.31 log10 copies/mL for NNRTIs [difference, -0.15 log10 copies/ml; 
95% CI, -0.41 to 0.11] or (b) proportion of children with viral loads <400 copies/mL at 4 years, 
which were 82% for PIs versus 82% for NNRTIs [OR 0.97; 95% CI, 0.49-1.91; Figure 3.1].45 
Given prior data on PIs being more efficacious than NNRTIs in lowering viral load,41 we 
hypothesize that this lack of difference in viral suppression between PIs and NNRTIs was due to 
worse adherence to PIs, yet greater efficacy of PIs in poor adherence.
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Figure 3.1. Viral suppression and CD4 percentage changes during follow-up in the 
PENPACT-1 trial. Vertical line indicates 4 years after randomization, the primary endpoint. 
CD4%: CD4 percentage; NNRTI: non-nucleoside reverse transcriptase inhibitor regimen; PI: 
protease inhibitor regimen; higher: higher viral load switch threshold (30,000 copies per mL); 
low: lower switch threshold (1,000 copies per mL). Reprinted from Lancet Infectious Diseases, 
Vol. 11, PENPACT-1 (PENTA 9/PACTG 390) Study Team, Babiker A, Castro nee Green H, et 
al., First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse 
transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an 





C. Aim 1: Assess PENPACT-1 Participants for Differences in Time to Treatment 
Disruption Across Randomized PI vs. NNRTI Treatment Arms at 4 Years and End of 
Study 
C1. Study Design 
We will perform a secondary analysis of data from a randomized, controlled trial 
(PENPACT-1) comparing pediatric ART with PIs versus NNRTIs for their effects on time to 
treatment disruption at the parent study’s primary endpoint of 4 years and end of study. 
C2. Treatment Assessment 
The parent study randomized 266 participants to PIs vs. NNRTIs, of which 263 were 
started on ART. Randomization was stratified by age (<3 years or ≥3 years), region (PACTG or 
PENTA centers), and exposure to perinatal ART to reduce mother-to-child transmission. 
Computer-generated sequentially numbered randomization lists (with variable block sizes) were 
prepared by the trial statistician (who was not involved in regimen allocation) and securely 
incorporated within the PACTG or PENTA databases, which allowed access to the next number 
but not the whole list. This study was an open-label study with no masking.   
This analysis will be a modified ITT analysis, excluding three of 266 participants (1%) 
who never started ART and four (2%) that were treated contrary to randomization. The primary 
analysis will explore whether the regimen contained either a PI or an NNRTI, regardless of other 
drugs in the regimen. PIs will include lopinavir, nelfinavir, ritonavir, saquinavir, indinavir, 
amprenavir, fosamprenavir, atazanavir, tipranavir, and darunavir. PIs given concomitantly to 
low-dose ritonavir will be defined as boosted PI regimens, whereas PIs not given concomitantly 
to low-dose ritonavir will be defined as unboosted PI regimens. NNRTI regimens will include 
nevirapine, efavirenz, delaviridine, and etravirine. Treatment groups will be classified according 
to randomized 1st line regimen, PI versus NNRTI. Treatment categorization will begin at the date 
of randomization.  
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C3. Outcome Assessment 
We will define time to treatment disruption as the number of weeks between 
randomization and the first documented treatment disruption event. We will derive treatment 
disruption events from the trial treatment records and adherence questionnaires. We will define 
treatment disruption as stopping, switching, or reporting missed doses of any component of the 
initial ART regimen for any reason other than systematic drug recalls or planned treatment 
interruptions. 
Treatment record events were recorded at clinical visits and ad hoc throughout the study. 
Participant treatment records recorded all treatment events, including ART starts, stops, 
temporary suspensions, restarts, drug substitutions, regimens switches, line of ART regimen, and 
reasons for the treatment events. Treatment disruptions derived from the treatment record will 
include ART stoppages (including stops and temporary suspensions) or switches (including drug 
substitutions and regimen switches). 
Trained study personnel administered validated adherence questionnaires every 24 weeks 
after randomization. Adherence questionnaires recorded the number of missed doses to all 
antiretrovirals over the 3 days prior to visit and barriers to adherence experienced within 2 weeks 
prior to visit. Treatment disruptions derived from the questionnaire will include any 
questionnaire-reported missed doses within 3 days prior to the study visit. 
If the participant had assumed responsibility for his/her own drug regimen, the 
questionnaire was administered to the participant (Appendices II and III). The questionnaire’s 
adherence measures will use answers to the following questions: 
• Primary Question: Over the last 3 days, can you say how many times, (sic) you have 
missed a dose?  (The response options include a global “no missed drugs” option or a 




• Secondary Question: 
o If you have missed any doses during the last two weeks, please tick the reason(s). 
If the participant had not assumed responsibility for his/her own drug regimen, the 
questionnaire was administered to the participant’s primary caregiver, i.e., the person responsible 
for administering the prescribed drugs at home (Appendices II and III). In this case, the questions 
to be used for adherence measures are: 
• Primary Question: Over the last 3 days, can you say how many times, (sic) your child has 
missed a dose? (The response options include a global “no missed drugs” option or a 
response itemizing individual drugs and numbers of doses missed in each of the past 3 
days.)  
• Secondary Question: 
o If your child has missed any doses during the last two weeks, please indicate the 
reason(s) and say which drug(s). 
Any acknowledgement of missed doses in 3 days or 2 weeks will be defined as poor, as 
consistent with the initial validation study.61 Validity of binary categorization, rather than more 
detailed response levels, will be explored with categorical analysis. 
Adherence questionnaires were standardized within according to research networks 
(PENTA vs. PACTG), and the protocol teams worked to harmonize the questionnaires across 
networks (Appendices II and III). Questions regarding number of missed doses over the 3 days 
prior to clinic visit were consistent across network questionnaires, as were the 14-day periods of 
assessments for reasons for non-adherence. However, differences in choices listed for reasons for 
non-adherence, listed tools used to support adherence, and protocol specific regarding who 
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administered or answered the questionnaires may result in heterogeneity of responses across 
networks, ages, and respondents regarding these specifics.  
As a result, questionnaire components of outcomes will focus on the more reliable 
questionnaire measures. For the primary outcome, time to treatment disruption will include the 
questionnaire inquiry regarding missed doses over the prior 3 days. For secondary outcomes, we 
explore the reasons listed for missed doses of the prior 2 weeks.  
C4. Covariate Assessment 
Since we will be analyzing treatments across randomized arms using an ITT analysis, we 
will rely on randomization to average across differences in treatment arms. However, 
randomization was stratified on age (<3 vs. 3-17 years), exposure to perinatal antiretrovirals (yes 
vs. no), and research network/region (PACTG/IMPAACT vs. PENTA). Thus, the randomization 
protocol introduced a stratified data structure, for which we will account in additional analyses, 
using these stratification variables as covariates.  
C5. Statistical Analyses 
PI vs. NNRTI treatment groups will be assessed according to a modified ITT analysis 
consistent with the original study. The sole modification will be removal of three participants: 
two who withdrew consent prior to ART initiation, and one with a major eligibility violation. 
Follow-up will begin at date of randomization. Participants will be right-censored for initial 
treatment contrary to randomization, planned treatment interruption, death, withdrawal of 
consent, loss to follow-up, or study end.  
Additional analyses will include adjustment for stratified randomization factors (age, 
receipt of perinatal ART prophylaxis, research network), assess differences in outcome for the 
primary follow-up time point (4 years) vs. the entire study, and explore reasons for treatment 
disruptions. Reasons for treatment disruptions will be analyzed using (1) the treatment record’s 
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documented rationale for ART stop or change and (2) any questionnaire-reported barriers to 
adherence within 2 weeks prior to the visit when missed dose(s) were reported.  
We will also assess the sensitivity of our results to our definition of treatment disruption. 
Our alternative outcome definitions will include: restricting treatment record treatment 
disruptions to drug changes or stops lasting more than 3 days or 14 days, restricting treatment 
record treatment disruptions to only events including the PI or NNRTI drug component, 
including two consecutive missing adherence questionnaires (plus a 6-week lag for a late visit) as 
a treatment disruption, and right-censoring after two consecutive missing adherence 
questionnaires. 
For the primary outcome, we will estimate the risk of treatment disruptions using the 
complement of the Kaplan-Meier estimator. We will estimate the hazard ratio for treatment 
disruptions using Cox proportional hazards models. Proportional hazards assumptions will be 
assessed graphically, using time-interaction terms, and with martingale residuals. In adjusted 
analyses, we will stratify by baseline randomized stratification variables: age, exposure to 
perinatal ART, and research network (which varied by region). 
Analyses will be conducted in SAS® version 9.4 (Cary, NC). 
C6. Limitations 
Our principal limitation is expected to be measurement error. First, we have no direct 
measures of drug exposure, such as therapeutic drug monitoring. Treatment records can only 
capture prescribing events and documented ART disruptions, and the adherence questionnaires 
rely on accurate reporting by either the child or the caregiver, if present and willing to answer. 
Second, missing questionnaires or refusal to answer portions of the adherence questionnaire may 
bias results. Third, adherence questionnaires in this study focus on ART adherence over the 3 
days prior to the most recent visit and inquire about adherence barriers encountered over the 
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prior 2 weeks, rather than a daily measure of adherence throughout the study. The time-varying 
nature of treatment disruption means that participants may experience an initial or temporary 
period of treatment disruption that is subsequently corrected, but our analysis will present only 
data on time to the first event of treatment disruption. Finally, heterogeneity of adherence 
questionnaires across networks, ages, and respondents regarding reasons for treatment disruption 
may limit interpretability of these responses despite efforts to harmonize these questionnaires. 
C7. Addressing Limitations 
To mitigate the potential information bias from reporting biases and missing data, we are 
designing our study to evaluate a composite outcome. Our combining treatment records and 
adherence questionnaires into a composite outcome should decrease measurement error from 
either instrument individually. 
Secondly, we are using a previously validated pediatric adherence questionnaire. 
Responses to this questionnaire were associated with concurrent viral suppression and decline in 
viral load from baseline (Table 3.2), which varied by week of study.61 Differences in reported 
adherence were associated with the questionnaire respondent (child, biological parent, other) and 
medication formulation (liquid vs. tablet/powder). The questionnaire analysis relied on missed 
doses over the prior 3 days, which serves as the basis for our approach. This question has been 
the most validated of the questionnaire and the most commonly used in the research literature.101 
However, performance characteristics of this questionnaire have not been validated against a 
gold standard measure of adherence.  
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Table 3.2. Associations with full adherence (FA) reported on questionnaire. Reproduced 




Thirdly, we have performed an analysis to confirm that the questionnaires have predictive 
value for viral control in the PENPACT-1 data. Linear mixed effects models evaluating the 
relationship between the adherence questionnaire (missed doses in past 3 days) and viral load 
suggest that this questionnaire performs at least reasonably well as a measure of adherence over 
the first 24 weeks of ART, when ART resistance is less likely (Table 3.3, Appendix IV Figure 
S1). Additionally, the adherence questionnaire response proportion was high (91%), without 
significantly differential response according to drug regimen (P = 0.87). Thus, we expect to 
obtain reliable results from Aim 1. 
 
Table 3.3. Differences in decline of HIV RNA log10 copies/mL decline over 24 weeks of 
ART by adherence category. 
Questionnaire-
Reported Adherence 
Decline of HIV RNA 
log10 copies/mL 














Missing data from questionnaire nonresponse may bias results. To assess whether the 
data may be missing at random, we have assessed potential relationships between baseline 
variables and missing questionnaires. Although race may have some association with 
missingness, most variables do not appear strongly associated (Table 3.4).  
 
Table 3.4. Baseline characteristics of 263 HIV-1-infected, treatment-naïve children initiated 
on 1st line ART with distribution of missing values. 




Missing Total Missingness 
P value 
Age at ARTa 
Initiation 
  0 to <3 years 
  3 to <6 years 
  6 to <13 years 





























  Male 



















  Black 



















  Protease Inhibitor 


















Viral Load Threshold  
  for ART Switch 
  ≥1,000 copies/mL 
























Baseline Viral Load 














Total N (%) 192 (89) 24 (11) 47 263 (100)  
aART=antiretroviral therapy; NNRTI=non-nucleoside reverse transcriptase inhibitor 
 
 
 With respect to the time-varying nature of adherence, our analytical approach is limited 
to only the first episode of treatment disruption, rather than multiple changes over time. 
Nevertheless, the time to first treatment disruption remains a clinically meaningful outcome, as 
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duration of time on initial therapy measures durability, tolerability, and general treatment 
response. 
In addition, our preliminary analysis of changes in adherence over time does not indicate 
major changes in reported adherence over time. This constancy of response was both 
longitudinal across repeated questionnaires over time and similar across different questions. 
Comparing regimens across randomized arms by univariable logistic regression with generalized 
estimating equations for repeated measures over 192 weeks of follow-up, we found that point 
estimates leaned toward more difficult adherence to PI-based regimens than NNRTI-based 
regimens (Table 3.5). Thus, missed doses over the last 3 days likely represent characteristics of 
the participant-drug-adherence relationships over time and across questionnaire responses. Thus, 
the time to the first treatment disruption event is likely a meaningful outcome. 
 
Table 3.5. Comparison of adherence questionnaire responses by ART regimen. 





Poor Adherence in Past 3 Days 1.34 0.81-2.23 
Adherence Problems in Past 2 Weeks 1.21 0.68-2.17 
Difficulty Remembering to Give 
Medications 
1.18 0.59-2.36 
Medications Interfere with Child’s Everyday 
Life 
1.45 0.88-2.40 
aPI=protease inhibitor-based regimen; NNRTI=non-nucleoside reverse transcriptase inhibitor-based 
regimen 
 
 Finally, the heterogeneity of adherence questionnaires across networks remains a 
limitation. We will focus on the most harmonized portion of the questionnaire, missed doses over 
the prior 3 days. We will work to harmonize the remainder of the questionnaire on reasons for 




C8. Data Interpretation 
We will interpret results based on hazard ratios relative to the null of 1 and the precision 
by width of 95% confidence intervals (95% CI). We will not rely on statistical significance. This 
study sample size was powered to evaluate this outcome using null-hypothesis testing. 
The reasons for treatment disruption will be listed to help explain the primary results. 
Given the heterogeneity of questionnaire questions regarding reasons for treatment disruption, 
we will regard this analysis as only descriptive.  
D. Aim 2: Estimate the Per-Protocol Effect of Initial PI versus NNRTI-Based ART on Time 
to Treatment Failure in Treatment-Naïve Children Living with HIV in Developed 
Countries in a Setting of Ideal Adherence. 
D1. Study Design 
We will perform a secondary analysis of data from the randomized PENPACT-1 trial 
estimating adherence-corrected differences in HIV RNA viral load control by initial PI- vs. 
NNRTI-based ART regimen. We will first replicate the trial’s ITT analysis, substituting a 
primary outcome of viral failure over 4 years. Then, we will conduct a per-protocol analysis that 
accounts for protocol non-adherence by (1) censoring patients who cease their assigned therapy 
for non-medically indicated reasons and (2) correct for imparted selection bias using inverse-
probability of censoring weights (IPCW), as described below. 
D2. Intention-to-Treat versus Per-Protocol Estimate 
The intention-to-treat (ITT) parameter estimates the effect of being assigned to a 
treatment protocol. In standard ITT analysis of clinical trials, poor adherence typically biases 
estimates of effective treatments towards the null, resulting in under-estimation of treatment 
efficacy and over-estimation of treatment safety.102 
The per-protocol parameter estimates the effect of being assigned to, and remaining on, a 
treatment protocol. Robins and Finkelstein (RF) introduced inverse probability of censoring 
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weights (IPCW) to account for non-indicated treatment disruptions, whether by stoppage or 
switching of assigned therapy, or by study dropout; and describe a consistent estimator of the 
per-protocol effect.95 This RF approach administratively censors study participants who cease to 
follow the assigned protocol, for instance, stopping or switching medications for reasons other 
than medical indications, such as adverse events. The approach then up-weights similar 
participants remaining under study to correct for induced informative censoring. The RF 
provides a principled way to address problematic post-randomization protocol violations, such as 
poor adherence and study dropout, which may affect clinical trial results. 
D3. Treatment Assessment 
The primary exposure will be the randomized initial PI- or NNRTI-based ART regimen, 
but we will define the population according to the original trial’s ITT analysis, which excluded 
three (1%) of participants who were not started on ART. After performing the ITT analysis, we 
will perform a per-protocol analysis that corrects for post-randomization factors that define 
protocol deviations.  
D4. Outcome Assessment 
Our primary outcome will be time to treatment failure, defined as viral failure or clinical 
failure within 4 years of randomization. Time to viral failure will be defined at the first of two 
consecutive viral loads >400 copies/mL at or after Study Week 24 (≥20 weeks after 
randomization). Because the protocol only required viral load confirmation of viral failure at 
higher viral loads (>1,000 copies/mL or >30,000 copies/mL) and other factors leading to missed 
viral load measurements (such as dropout, not returning for labs, and protocol deviations), many 
viral loads >400 copies/mL were not confirmed within a short time frame. Thus, we will use the 
next measured viral load value, regardless of time interval, to confirm viral failure.  
Clinical failure will be defined as clinical disease progression, namely a new Centers for 
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Disease Control and Prevention (CDC) stage C event (generally equivalent to a CDC stage 3 
clinical event in the 2014 staging guidelines),103,104 or other clinical progression such that the 
treating clinician believed that changing therapy was required prior to reaching the viral load 
switch point. Time to clinical failure will be defined at documentation of the event in the 
treatment record or case report form. 
D5. Protocol Deviations 
Protocol deviations will be defined as any non-medically indicated stoppages or changes 
of any component of the initially prescribed ART regimen that result in the participant receiving 
fewer than two NRTIs or not receiving the assigned class of PI or NNRTI at any time. The 
assigned class of PI or NNRTI on first line ART must be according to randomized arm; the 
assigned class on second line ART must be the reverse of the originally randomized class. Any 
switch to a third line or other regimen will be considered a protocol deviation. Participants 
receiving both a PI and an NNRTI at the same time or use of other classes, such as integrase 
inhibitors or fusion inhibitors, will be defined as protocol deviations, regardless of the reason for 
the prescription change.   
ART medication stoppages or changes will be captured from both treatment records and 
adherence questionnaires. From treatment records, we will define medically indicated reasons for 
ART stoppages or changes as adverse events, viral failure, resistance, death, pregnancy, regimen 
simplification, or medication switches within the same antiretroviral class. During the parent 
study, nelfinavir underwent a drug recall. Any immediate switch to another drug within the same 
class for a nelfinavir recall or other drug supply problem will be defined as a non-protocol 
deviation, but any interruption of ART or switch to another drug class will be defined as a 
protocol deviation, as other drugs within the same class should have been available. 
Because a medically indicated reason for ART stoppage or change would require a 
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clinician to determine the indication, any missed dose reported on the adherence questionnaire, 
regardless of reason, will be defined as a non-medically indicated stoppage. Study dropout, 
defined as cessation of viral load measurements before 4 years on study, will be counted as a 
protocol deviation. All non-medically indicated ART stoppages or changes and all dropouts will 
be defined as protocol deviations at their first occurrence.  
D6. Covariate Assessment 
To determine the most appropriate covariates, we constructed a causal diagram to analyze 
time-varying relationships among treatment regimen, protocol non-adherence, and viral load (Fig 
3.2, Appendix IV Figure S2). The relevant paths in this analysis are those paths that affect both 
protocol non-adherence and viral load. Potential time-fixed covariates will include age at 
enrollment (<3 vs. 3-17 years), exposure to perinatal antiretrovirals, research network/region 
(PACTG/IMPAACT vs. PENTA), route of HIV exposure (vertical vs. other), baseline CDC 
clinical staging (stage C or not, categorized by the 1994 revised CDC classification system,103 as 
used by the parent study), baseline CD4 cell count (stage 1 vs. 2 or 3, categorized according to 
2014 CDC immunologic criteria104), and baseline log10 viral load. Potential time-varying 
covariates will include most recent categorized CD4 cell count from the prior visit, most recent 
log10 viral load from the prior visit, and an ART switch indicator variable. New HIV-related 
clinical manifestations on ART were not included because they were rare and may lead to 
positivity violations. Covariates ultimately included in models may be reduced based on 








 All covariate data will be from the original data collected in the PENPACT-1 parent 
study. Variable coding will be defined according to CDC staging,103,104 trial definitions, and 
exploration of data fit by splines105 and polynomial expansion. 
D7. Statistical Analysis 
We will contrast PI vs. NNRTI treatment arms as randomized in the parent study’s 
modified ITT analysis, which included only participants who started ART, and then perform a 
per-protocol analysis accounting for post-randomization protocol non-adherence in the same 
study population.  
First, we will perform an unweighted analysis of the original data to generate modified 
ITT estimates. Follow-up will begin at the date of randomization. Participants will be right-
censored at dropout or 4 years on study. Four years of follow-up will be defined as the week 204 
visit plus a 6-week lag to capture late visits. Participants will be followed until their last 
documented viral load, viral failure, or 4 years, whichever occurred first. 
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Then to perform the per-protocol analysis, we will re-analyze the data using Robins-
Finkelstein (RF) inverse probability-of-censoring weights (IPCW) applied to longitudinal studies 
with baseline randomization. Any participant who experiences a protocol deviation will be right-
censored at that time. Then we will apply RF-IPCW to corrected for imparted informative 
censoring, as described by Robins and Finkelstein95 and by Cain and Cole88: 
Notation 
Let  
i index 1 to N = 263 participants 
j index 1 to J = 210 weeks from ART initiation 
Rij = 1 indicate that participant i is at risk for treatment failure on day j,  
0 otherwise 
Dij = 1 indicate that participant i experienced treatment failure at day j,  
0 otherwise 
Cij = 1 indicate that participant i dropped out or became protocol non-adherent 
before day j, 0 otherwise  
 Xi = 1 indicate that participant i was allocated to receive initial ART with a PI,  
0 otherwise 
 Zij = 1 indicate that participant i was exposed to ART with a PI,  
0 otherwise 
 Z̅ij denote the history of Zij up through j, i.e. Z̅ij = {Zi0 , Zi1 , … , Zij} 
 Vij denote a vector of time fixed (i.e. at ART initiation, j = 0) and time-varying  
covariates  
Dij(z̅) = 1 indicate that participant i experienced viral failure on day j,  
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given participant i had exposure history z̅, 0 otherwise  
Dij(z̅) is a potential outcome, signifying an outcome which may be contrary to fact. We will 
assume exchangeability as no informative censoring given treatment allocation and measured 
time-fixed and time-varying covariates, formally defined as: 
 P(Cij = 0 | Xi , V̅ij-1) = P[Cij = 0 | Xi , V̅ij-1 , Dij(z̅)] 
 
Robins-Finkelstein (RF) Inverse Probability-of-Censoring Weights 
We will use RF inverse probability-of-censoring weights to correct for possible bias 
induced by dropout, death, or artificial censoring due to protocol non-adherence.  
Weights Wij are defined below: 
 If Cij = 1 then Wij = 0 
 If Cij = 0 then Wij =  
∏
𝑃(𝐶𝑖𝑘 = 0 |𝑋𝑖)





Thus, on or after censoring, zero weights are applied. Prior to censoring, positive weights 
are applied. Positive weights will upweight uncensored patients (conditional on allocated ART 
and measured time-fixed and time-varying covariates) to compensate for imparted informative 
censoring, while stabilizing by the probability of remaining uncensored on day j conditional on 
allocated ART.   
The conditional probabilities for the weights’ numerators and denominators will be fit 
using pooled logistic regression models for the hazard of censoring as below: 
 logit P(Cij = 0 | Xi) = α0j + α1Xi   (weight numerator) 
 logit P(Cij = 0 | Xi , V̅ij-1) = β0j + β1Xi + β2’V̅ij-1 (weight denominator) 
 where  
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α0j and β0j are week-specific intercepts 
α1  is the log hazard ratio for censoring comparing PI vs. NNRTI 
β1 is the log hazard ratio for censoring comparing PI vs. NNRTI among  
patients with the same covariate history V̅ij-1 
β2’ is the transpose of the column vector of the log hazard ratio for the  
components of the covariate history matrix V̅ij-1 
IPCW will be calculated separately for each treatment arm. Week-specific intercepts will 
be fit using splines fit according to the data by treatment arm to stabilize weights. If time-varying 
values are missing, we will carry forward the last observed value.  
To clarify our approach, please note that the fitted pooled logistic regression will be used 
to estimate the probability of not being censored for protocol deviations using baseline and time-
varying covariates for each participant at each week under study. This probability will be applied 
as the denominator of the IPCW, and week on randomization will be applied as the numerator to 
stabilize the weights.  
By applying these weights, participants remaining under study will be up-weighted, using 
the inverse of the probability of remaining free from a protocol deviation, to replace an 
equivalent number of participants who were censored. Censoring and up-weighting will be 
applied cumulatively at the week of each protocol deviation until the end of 4 years on study. 
Similar to the modified ITT analysis, follow-up will begin at randomization, and participants will 
be right-censored without up-weighting at 4 years on study. 
Regression Models 
For the primary outcome, we will estimate the risk of viral failure using the complement 
of the Kaplan-Meier estimator, unweighted for modified ITT analysis and applying IPCW for the 
 
40 
per-protocol analysis. We will estimate the hazard ratio (HR) for viral failure using a Cox 
proportional hazards model, unweighted and weighted. Proportional hazards assumptions will be 
assessed graphically, using time interaction terms, and with martingale residuals. In adjusted 
analyses, the ITT analysis will be stratified by baseline randomized stratification variables: age, 
exposure to perinatal antiretrovirals, and research network (which varied by region). For the per-
protocol analysis conditional on randomized stratification variables, we will include the 
randomized stratification variables to the final reduced model for IPCW. All confidence intervals 
will be estimated using the robust sandwich variance estimator with an independent working 
covariance matrix. 
Finally, we will assess the sensitivity of our results to changes in our model 
specifications. Given the relation between time-varying viral load from the prior visit and viral 
failure, an alternative IPCW model will excluded time-varying viral load. Other alternative 
IPCW models will exclude the weakest predictor(s) of censoring and include only randomized 
stratification variables. Sensitivity analyses will assess the extremes of corrections for censoring 
protocol deviations by (1) estimating effects without applying IPCW; (2) assuming all censored 
participants in the PI arm are failures and all censored participants in the NNRTI arm are non-
failures; and (3) reversing this latter coding.   
Analyses will be conducted in SAS® version 9.4 (Cary, NC). 
D8. Potential Limitations 
Although PENPACT-1 is one of the largest pediatric HIV trials, the sample size may still 
limit the number of covariates that may be included in the model, potentially presenting tensions 
between sufficient covariate control for exchangeability versus maintaining positivity. Moreover, 
the study will suffer from measurement error from incomplete capture of treatment disruptions 
on the treatment record or inaccurate reporting of non-adherence on the questionnaire. Finally, 
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the traditional viral failure outcome has limitations as (1) a composite outcome that combines 
distinct events of viral suppression and viral rebound and (2) assignment of pre-determined 
failure time, e.g. 24 weeks of ART, for patients who fail to achieve viral suppression, rather than 
a more specific time to suppression. 
D9. Addressing Potential Limitations 
Regarding he limited sample size potentially compromising exchangeability and 
positivity assumptions, this limitation cannot be corrected. We accept this limitation but expect 
that we will have improved validity of this method over methods that would not account for post-
randomization protocol deviations.  
As to the measurement error resulting from treatment records and adherence 
questionnaires, the composite variable of protocol non-adherence from either measure should 
decrease the measurement error from either instrument alone. In addition, the validity of the 
questionnaire has previously been evaluated,61 and our preliminary data suggests some predictive 
value of the questionnaire (See Section C7). Measurement error is inherent in any adherence 
measure, and we are left with the adherence measure used in the study.  
Finally, if the data suggest a need to separate the composite outcome of viral failure, then 
we will employ the method proposed by Gouskova et. al., which uses an endpoint based on the 
probability of being virally suppressed.106 This method estimates the difference in survival 
functions for viral suppression and viral rebound and may be used to estimate differences in 
mean total time of viral suppression. We will use this method if the proposed traditional 
composite endpoint suggests an interaction across time, such as survival functions crossing one 
another. An example of this scenario would be if one treatment arm has a lower probability of 




D10. Data Interpretation 
Our data interpretation will focus on the shift in hazard ratios and 95% CIs from the ITT 
to the per-protocol analysis. The ITT analysis would estimate treatment efficacy in the setting 
where protocol non-adherence is permitted. The per-protocol analysis estimates treatment 
efficacy in the setting of participants adhering to the prescribed protocol. In this case, shifts in 
ITT to per-protocol estimates would indicate how robust the PI or NNRTI ART regimens are to 
non-adherence. Greater shifts would suggest that non-adherence has a greater influence on 
treatment failure. We will interpret results under assumptions of ITT, per-protocol, and the 
degree of shift between the two analyses. 
E. Conclusion 
Adherence to ART is a major determinant of pediatric HIV treatment outcomes. 
Although many approaches to improving adherence have been proposed, prescribing patterns are 
the most modifiable by clinicians. PIs and NNRTIs are key drugs that may be modified, but the 
relationships are not well-defined among drug, adherence, and viral control. Therefore, we 
propose to disentangle drug-adherence and adherence-viral control relationships in a randomized 
controlled trial of PI vs. NNRTI ART in children. The results generated may help determine the 
influence of prescription decisions for HIV-infected children on time to treatment disruption and 
time to treatment failure when accounting for these treatment disruptions.
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CHAPTER 4: TIME TO TREATMENT DISRPTION IN CHILDREN RANDOMIZED 
TO PROTEASE INHIBITOR VERSUS NON-NUCLEOSIDE REVERSE 
TRANSCRIPTASE INHIBITOR REGIMENS 
A. Overview 
Background: Choice of initial antiretroviral therapy (ART) regimen may help HIV-
infected children maintain optimal, continuous therapy. We assessed treatment-naïve children for 
differences in time to treatment disruption across randomly-assigned protease inhibitor (PI) 
versus non-nucleoside reverse transcriptase inhibitor (NNRTI)-based initial ART. 
Setting: We performed a secondary analysis of a multicenter phase 2/3, randomized, 
open-label trial in Europe, North and South America from 2002-2009. 
Methods: HIV-1-infected, ART-naïve children aged 31 days to <18 years were 
randomized to ART with two nucleoside reverse transcriptase inhibitors plus a PI or NNRTI. 
Time to first documented treatment disruption to any component of ART, derived from treatment 
records and adherence questionnaires, was analyzed using Kaplan-Meier estimators and Cox 
proportional hazards models.  
Results: The modified intention-to-treat analysis included 263 participants. Seventy-two 
percent (n = 190) of participants experienced ≥1 treatment disruption during study. At 4 years, 
treatment disruption probabilities were 70% (PI) vs. 63% (NNRTI). The unadjusted hazard ratio 
(HR) for treatment disruptions comparing PI vs. NNRTI-based regimens was 1.19, 95% 
confidence interval [CI] 0.88-1.61 (adjusted HR 1.24, 95% CI 0.91-1.68). By study end, 
treatment disruption probabilities converged (PI 81%, NNRTI 84%) with unadjusted HR 1.11, 
95% CI 0.84-1.48 (adjusted HR 1.13, 95% CI 0.84-1.50). Reported reasons for treatment 
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disruptions suggested that participants on PIs experienced greater tolerability problems.  
Conclusions: Children had similar time to treatment disruption for initial PI- and NNRTI-
based ART, despite greater reported tolerability problems with PI regimens. Initial pediatric 
ART with either a PI or NNRTI may be acceptable for maintaining continuous therapy.   
B. Introduction 
Globally, 1.8 million children are living with HIV, and 110,000 die annually due to 
AIDS-related illnesses.1 For HIV-infected children, greatest survival outcomes can be achieved 
only with optimal, uninterrupted treatment on effective antiretroviral therapy (ART). Treatment 
disruptions, defined as any interruption or alteration of initial ART, may result from patient-level 
factors (e.g., poor adherence, drug intolerance), provider-level factors (e.g., prescription stops, 
changes, or errors), or systems-level factors (e.g., stock outs, interruptions in drug delivery). 
Unfortunately, treatment disruptions may result in treatment failure, acquisition of resistance 
mutations, and loss of future treatment options—which are particularly consequential in children. 
Compared with adults, children have greater pharmacokinetic variability and fewer available 
licensed drugs.4,85 Due to longer lifetime antiretroviral exposure, children have more potential for 
long-term toxicity.16,17 Children have greater social vulnerability related to their dependence on 
others for medical care and medication administration.20,107 If inadequately treated, children 
progress more rapidly to HIV disease and death.2,86,108 As children’s initial ART regimens are 
often their best opportunity for effective, tolerable treatment, longer time on their initial regimen 
generally means greater efficacy, fewer toxicities, and more lifetime treatment options. 
Analyzing longitudinal relationships between pediatric ART regimens and time to treatment 
disruption allows identification of initial ART regimens that pose greater challenges to 
maintaining optimal, continuous ART.  
 When deciding which regimen to prescribe to optimize clinical outcomes, clinicians must 
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consider both drug pharmacology and potential adherence to ART regimens.109 Boosted 
protease-inhibitor (PI)-based regimens appear more forgiving of treatment disruptions than do 
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens.55,57,60,96,98 However, 
certain PI characteristics decrease adherence and tolerability, particularly in children: poor taste; 
gastrointestinal toxicity; and regimen complexity, such as pill burden, storage requirements, and 
dosing frequency.18-20,41,60,110,111 Prior pediatric studies that have assessed the ability of children 
to maintain continuous therapy did not do so in settings in which use of PI- vs. NNRTI-based 
ART regimens was randomly allocated, nor have prior studies measured treatment disruptions 
longitudinally. As a result, these previously conducted studies have potential for residual 
confounding from unmeasured covariates. Furthermore, most studies have isolated analyses of 
prescription patterns, adherence, and tolerability, rather than evaluating the total effect of the 
regimen on maintaining optimal, continuous therapy. In the PENPACT-1 study, 266 HIV-1-
infected, treatment-naïve children from Europe, North America, and South America were 
randomized to ART with either a PI or NNRTI and followed longitudinally for at least 4 years.45 
We aimed to assess PENPACT-1 participants for differences in time to treatment disruption 
across randomized PI vs. NNRTI treatment arms at 4 years and end of study.  
C. Methods 
C1. Study Design and Participants 
PENPACT-1 (PACTG 390 / PENTA 9) was an international multicenter phase 2/3, 
randomized, open-label trial enrolling children infected with HIV-1 from 68 clinical centers in 
13 countries in Europe and North and South America between September 25, 2002, and 
September 7, 2005.45 Eligible children aged 31 days to less than 18 years were HIV-1-infected 
and had not received ART or received only antiretrovirals for <56 days to reduce mother-to-child 
transmission (excluding single-dose nevirapine). All parents or guardians and children, as 
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appropriate, gave written consent for the parent trial; this protocol was conducted in accordance 
with the Declaration of Helsinki and approved by the relevant ethics committee or institutional 
review board (IRB) for each participating center. The secondary analysis on time to treatment 
disruption was deemed exempt by the Duke University IRB and approved by the University of 
North Carolina-Chapel Hill and Children’s Mercy Kansas City IRBs. This study is registered 
with the International Standard Randomised Controlled Trial Number Registry 
(ISRCTN73318385). 
Children were randomized 1:1 to start ART with two nucleoside reverse transcriptase 
inhibitors (NRTIs) plus either a PI or NNRTI. The study was open label, and the treating 
clinician chose the two NRTI drugs combined with a drug from the randomly assigned PI or 
NNRTI class. Children underwent clinical and HIV-1 RNA viral load assessments at 
randomization (week 0), weeks 2, 4, 8, 12, 16, 24, and then every 12 weeks until the last child 
assigned to treatment reached 4 years of follow-up (August 31, 2009). Treatment starts, changes, 
and stoppages were recorded at clinical visits and ad hoc throughout the study. Trained study 
personnel administered validated adherence questionnaires every 24 weeks after 
randomization.61 Adherence questionnaires recorded the number of missed doses to all 
antiretrovirals over the 3 days prior to visit and barriers to adherence experienced within 2 weeks 
prior to visit. Four years of follow-up was defined as the week 192 visit plus a 6-week lag to 
capture late visits. 
C2. Outcomes 
We defined time to treatment disruption as the number of weeks between randomization 
and the first documented treatment disruption event. We defined treatment disruption as 
stopping, switching, or reporting missed doses of any component of the initial ART regimen for 
any reason except recall of nelfinavir (June 2007) or planned treatment interruptions. 
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Information on ART stoppages or switches was derived from participants’ treatment records, and 
missed doses were defined as any questionnaire-reported missed doses within 3 days prior to the 
study visit.  
Additional analyses included adjustment for stratified randomization factors (age, receipt 
of perinatal ART prophylaxis, research network), assessed differences in outcome for the 
primary follow-up time point (4 years) vs. the entire study, and explored reasons for treatment 
disruptions. Reasons for treatment disruptions were analyzed using (1) the treatment record’s 
documented rationale for ART stop or change and (2) any questionnaire-reported barriers to 
adherence within 2 weeks prior to the visit when missed dose(s) were reported.  
We assessed the sensitivity of our results to missing questionnaires by evaluating 
alternative definitions of treatment disruption. Our alternative outcome definitions included: 
including two consecutive missing adherence questionnaires (plus a 6-week lag for a late visit) as 
a treatment disruption, and right-censoring after two consecutive missing adherence 
questionnaires. 
C3. Statistical Analysis 
PI vs. NNRTI treatment groups were assessed according to a modified intention-to-treat 
(ITT) analysis consistent with the original study.45 The sole modification was removal of three 
participants: two who withdrew consent prior to ART initiation, and one with a major eligibility 
violation. Follow-up began at date of randomization. Participants were right-censored for initial 
treatment contrary to randomization, planned treatment interruption, death, withdrawal of 
consent, loss to follow-up, or study end.  
 For the primary outcome, we estimated the risk of treatment disruptions using the 
complement of the Kaplan-Meier estimator. We estimated the hazard ratio for treatment 
disruptions using Cox proportional hazards models. Proportional hazards assumptions were 
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assessed graphically, using time-interaction terms, and with martingale residuals. In adjusted 
analyses, we stratified by baseline randomized stratification variables: age, exposure to perinatal 
ART, and research network (which varied by region). Analyses were conducted in SAS® version 
9.4 (Cary, NC). 
D. Results 
PENPACT-1 enrolled 266 HIV-1 infected children from 68 centers in 13 countries in 
Europe, North America, and South America. The modified ITT analysis was restricted to 263 
participants who initiated ART. Participants were a median age of 6.5 years at enrollment (IQR 
[interquartile range], 1.8-12.9), 52% male, 49% black, and 79% exposed to HIV via vertical 
transmission (Table 4.1). Fifty-one percent had moderate to severe clinical symptoms (CDC 
stage B or C). Median growth parameters were below average (weight-for-age Z score -0.6; 
height-for-age Z score -0.9). Median CD4 Z-score was -3.5, consistent with predominance of 
moderate to severe immunosuppression, and median viral load was 5.0 log10 copies/mL. 
Whereas 15% of children had ART exposure for prevention of mother-to-child transmission, 4% 
had at least one major resistance mutation at baseline. Although treatment groups had differences 
in racial distribution, baseline characteristics relating to mode of HIV-1 acquisition, clinical and 
immunological status, and ART resistance were generally balanced across ART regimens, 
consistent with the randomized design.  
Median follow-up time was 261 weeks (IQR, 217-313). Two participants in each arm 
were started on a PI or NNRTI contrary to randomization; two underwent planned treatment 
interruption; five withdrew from study after ART initiation; 37 were lost to follow-up; and one 
patient died, due to HIV-related complications (Figure 5.1). Two hundred forty-nine participants 
ever completed an adherence questionnaire, totaling 2,112 questionnaires over the duration of the 
study for a mean of 8.5 questionnaires per participant.  
 
49 
 Overall, 191 of 263 participants had at least one treatment disruption event during the 
study, with 66% treatment disruption probability at 4 years (primary follow-up period) and 83% 
treatment disruption probability at study end (6.5 years). At 4 years, probabilities of treatment 
disruption were 70% vs. 63% in the PI and NNRTI arms, respectively (Figure 5.2). Hazards for 
treatment disruption, however, were similar for PI vs. NNRTI-based regimens (unadjusted 
hazard ratio [HR] 1.19, 95% confidence interval [CI] 0.88-1.61), even after adjustment for 
stratification factors of age, receipt of perinatal ART, and research network/region (adjusted HR 
1.24, 95% CI 0.91-1.68) [Table 4.2].  
After 4 years, treatment disruption probabilities converged, such that treatment disruption 
probabilities at study end were 81% for PI vs. 84% for NNRTI arms, but changes over time in 
the hazard ratio of treatment disruption by treatment arms were non-significant (unadjusted P for 
interaction = 0.33, adjusted P = 0.21). Hazards for treatment disruption over the entire study 
period were similar for PI vs. NNRTI-based regimens, unadjusted (HR 1.11, 95% CI 0.84-1.48) 
and adjusted (HR 1.13, 95% CI 0.84-1.50).  
 Of 191 treatment disruption events, 126 events were based on ART regimen stoppages or 
changes in the treatment record, and 67 events were reported missing doses on adherence 
questionnaires, with two participants experiencing both event types simultaneously. Of the 
treatment stops or changes, 25% of events were substitutions of at least one first-line ART drug 
(PI 32%, NNRTI 16%), 53% were stoppage or suspension of the entire first-line ART regimen 
(PI 48%, NNRTI 59%), and 22% were switches to a second-line ART regimen (PI 20%, NNRTI 
25%). Most frequent reasons documented for ART stops or changes were adverse events (34%), 
viral failure (22%), caregiver request (18%), non-adherence (7%), and temporary break (6%), 
with the greatest difference between PIs over NNRTIs for adverse events (Table 4.3).  
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Reports of missed doses on adherence questionnaires were balanced between PI and 
NNRTI arms, as 35% of non-adherence events in each arm were from patient or caregiver 
reports. The most common questionnaire-reported barriers to adherence, forgetting/lacking 
support (30%) or running out of medications (25%), were balanced between PI and NNRTI 
regimens. Other common questionnaire-reported adherence problems—including difficulties 
with administration, such as those attributed to intolerance, taste, patient refusal (24%); fear of 
disclosure to others (22%); patient refusal (21%); difficulties with scheduling or lifestyle (18%); 
and concerns about drug toxicity (16%)—were more frequently reported in participants in the PI 
arm (Table 4.3).   
Accounting for missing questionnaires by including at least two consecutive missed 
questionnaires as a treatment disruption event yielded 4-year hazard ratios close to the null 
(unadjusted HR 1.06, 95% CI 0.80-1.40; adjusted HR 1.08, 95% CI 0.81-1.43). Right-censoring 
participants with two consecutive missing adherence questionnaires produced 4-year hazard 
ratios similar to the primary analysis (unadjusted HR 1.20, 95% CI 0.88-1.63; adjusted HR 1.26, 
95% CI 0.92-1.72).  
E. Discussion 
In PENPACT-1, time to treatment disruption was similar in patients randomized to PIs 
and NNRTIs. Point estimates were mildly in the direction of more treatment disruptions in PI-
based regimens, particularly in the primary end point of 4 years, but differences were small, 
possibly due to chance, and appeared to decrease by study end. Exploration of reasons for 
treatment disruptions suggested that PI-based regimens may be less tolerable, both due to 
adverse events leading to treatment stoppages or substitutions and to regimen-specific adherence 
barriers reported on the adherence questionnaire. However, these PI-associated difficulties did 




Although we did not find a meaningful difference in treatment disruptions in PI vs. 
NNRTI-based regimens, the secondary analyses exploring reasons for treatment disruptions 
suggested that administration of a PI-based regimen to a child may be a struggle, even if not 
resulting in actual missed doses. The treatment record suggested that participants experienced 
more adverse events to PIs over NNRTIs, but adherence questionnaire responses formed a 
pattern of difficulties with PI tolerability, whether attributed to taste, medication volume or pill 
burden, toxicity, or simply patient refusal. This pattern would be consistent with existing 
literature on PI vs. NNRTI regimens. PIs have higher drug toxicity, especially gastrointestinal 
side effects, and intolerance, particularly regarding their noxious taste.18-20,41-44 Even if children 
are able to swallow pills, certain PIs are available only as large pills.89,112 No PIs are available as 
complete-regimen combinations for children, whereas single-tablet NNRTI regimens can 
facilitate adherence through administration of fewer pills.4,52,90-93 Participants reported more 
barriers to adherence in PIs related to scheduling or lifestyle interference, which may relate to 
dosing frequency. We hypothesize that increased fear of disclosure to others, as noted in the PI 
arm, may relate to difficulties concealing drug administration when given more frequently. 
Higher dosing frequency has been associated with more frequent treatment disruptions.18,48-52,90,92 
Some NNRTIs, most notably efavirenz, have more suitable pharmacokinetics for once daily 
administration. In our study, most PI-based regimens were administered at least twice daily, 
whereas some commonly used NNRTI-based regimens allowed once-daily dosing. 
Most children in PENPACT-1 experienced a treatment disruption event during the study. 
Only about one-third of participants remained continuously on their initial ART at 4 years; only 
one-sixth remained continuously on initial ART at study end. Maintaining continuous therapy on 
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ART is critical to sustained HIV-related outcomes, as suppressing viral load decreases the 
probability of HIV sub-populations acquiring antiretroviral resistance mutations and chances of 
forward infection.5,22,23,32-35,113,114 Although optimal adherence targets vary by PI vs. NNRTI 
class, adherence has been modest across ART studies, especially patients failing to achieve viral 
suppression.36,37,39,40,52-56,60,109 Notably, ART appears to be less successful in producing viral 
suppression in children, who are more prone to viral failure and resistance due to higher plasma 
viral loads, less robust antiviral immune responses, greater pharmacokinetic variability, and 
social dependency.5,21 Adolescents have particularly worse viral and immunological outcomes, 
due to poor ART adherence.22-25,115 The large proportion of children in PENPACT-1 with 
disruptions of their initial ART raises concerns regarding long-term durability, especially as 
these patients were receiving adherence support on a clinical trial protocol at specialty pediatric 
HIV centers. 
Based on our data, choice of an initial PI- vs. NNRTI-based regimen may not have a 
major impact on ART treatment disruption. Despite differences in reported regimen-related 
adherence barriers, participants in both treatment arms persevered in taking their regimens 
similarly. Moreover, the most common questionnaire-reported barriers were not regimen-
specific: forgetting/lack of support and running out of drug. Novel interventions may still be able 
to improve the experience of drug administration. Pediatric granules using nanotechnology may 
improve palatability and decrease pill burden, and precision medicine related to taste-sensing 
genotypes may hold promise for prescribing according to individualized palatability.116,117 In 
adult data, integrase strand transferase inhibitors (INSTIs) have been at least as tolerable as PIs 
or NNRTIs, if not more so, and INSTIs are increasingly preferred drugs in children.101,118-120 
Nevertheless, a primary goal of optimizing continuous therapy to ART is durable viral 
 
53 
suppression, which was comparable across PI vs. NNRTI arms in this study’s parent trial, 
although similar trials had variable results.45,84,99,100,121,122 In this study population, choice of 
either PI- or NNRTI-based initial ART appears acceptable. 
Our estimates of treatment disruption may have had measurement error. First, we had no 
direct measures of drug exposure, such as therapeutic drug monitoring. Treatment records 
captured only prescribing events and documented ART disruptions, and the adherence 
questionnaires relied on accurate reporting by either the child or the caregiver, if present and 
willing to answer. Although we relied on a questionnaire that has previously been validated,61 
reporting biases and unanswered questionnaires may have affected our measures of missed 
doses. Our combining treatment records and adherence questionnaires into a composite outcome 
should have decreased measurement error from either instrument individually. Second, 
adherence questionnaires in this study focused on ART adherence over the 3 days prior to the 
most recent visit and inquired about adherence barriers encountered over the prior 2 weeks, 
rather than a daily measure of adherence throughout the study. The time-varying nature of 
treatment disruption47,123 means that patients may have experienced an initial or temporary 
period of treatment disruption that was subsequently corrected, but our analysis presents only 
data on time to first event of treatment disruption. Third, limited participant report of individual 
drugs missed on the adherence questionnaire precluded definitive identification of treatment 
disruptions of individual drugs. Instead, we assessed treatment disruption to any component of 
the ART regimen. Fourth, heterogeneity of adherence questionnaires across networks, ages, and 
respondents regarding barriers to therapy should caution against rigorous interpretation of 
reasons for treatment disruptions. Finally, this study size was not sufficient to distinguish 




 In conclusion, children in PENPACT-1 had similar time to treatment disruption for initial 
PI-based regimens and NNRTI-based regimens. Although secondary analyses suggest that PI-
based regimens may be more difficult to tolerate and may be less convenient to administer, these 
difficulties did not result in a large difference in children stopping, changing, or missing doses at 
4 years (PI 70%, NNRTI 63%), and any suggested differences diminished by study end (PI 81%, 
NNRTI 84%). Initial ART with either a PI or NNRTI may be acceptable for maintaining 










Figure 4.2. Proportion of children experiencing treatment disruption from initial ART 
regimen by study week. The vertical line delineates 4 years on study. 
 




Table 4.1. Baseline characteristics of study participants according to initial ART regimen. 
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; N, total sample size; n, subsample size; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. 
a PENTA sites were predominantly in Europe, South America, and the Bahamas. PACTG/IMPAACT sites were 
based primarily in the United States. 
b Not all patients had successful baseline genotypic resistance assays.  
  
  Randomized Group 
Variable  PI NNRTI Total 
N  131 132 263 
Age  
  <3 years       
  3-17 years           
















6.5 (2.8, 12.9) 
Sex 










  Black, Non-Hispanic     
  White, Non-Hispanic    


















  PENTA                   













Route of Infection 
  Vertical 













CDC Clinical Stage 
  N 
  A                    
  B 





















Weight-for-Age Z-score Median (IQR) -0.5 (-1.6, 0.1) -0.7 (-1.6, 0.2) -0.6 (-1.6, 0.1) 
Height-for-Age Z-score Median (IQR) -0.9 (-1.5, -0.2) -0.9 (-1.8, 0) -0.9 (-1.7, -0.2) 
CD4 Z score Median (IQR) -3.6 (-7.2, -1.7) -3.4 (-6.5, -1.4) -3.5 (-6.8, -1.6) 
Viral Load log10 copies/mL Median (IQR) 5.1 (4.5, 5.7) 5.0 (4.5, 5.6) 5.0 (4.5, 5.7) 
Perinatal ART Exposure n (%) 19 (15%) 20 (15%) 39 (15%) 
≥1 Major Resistance Mutationb n/N (%) 5/116 (4%) 5/123 (4%) 10/239 (4%) 
HIV-1 subtype 
  B 
  C 
  F 
  A/CRF_AG/D/G 


























  1,000 copies/mL    













Duration of Follow-Up in weeks Median (IQR) 263 (217, 313) 260 (219, 316) 261 (217, 313) 
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Treatment disruption within 4 years 1.19 (0.88-1.61) 1.24 (0.91-1.68) 
Treatment disruption by end of study (6.5 years) 1.11 (0.84-1.48) 1.13 (0.84-1.50) 





Table 4.3. Reasons listed for treatment disruption events. 
Reason / Barrier  PI NNRTI Total 
Treatment Recorda     
    Adverse event n (%) 24 (37%) 19 (31%) 43 (34%) 
    Viral failure n (%) 13 (20%) 15 (25%) 28 (22%) 
    Caregiver request n (%) 11 (17%) 12 (20%) 23 (18%) 
    Non-adherence n (%) 6 (9%) 3 (5%) 9 (7%) 
    Temporary break n (%) 3 (5%) 5 (8%) 8 (6%) 
    Unknown n (%) 5 (8%) 1 (2%) 6 (5%) 
    Drug supply problem n (%) 1 (2%) 2 (3%) 3 (2%) 
    Intercurrent illness n (%) 0 (0%) 2 (3%) 2 (2%) 
    Resistance n (%) 1 (2%) 1 (2%) 2 (2%) 
    Parent forgot n (%) 1 (2%) 0 (0%) 1 (1%) 
    Simplification n (%) 0 (0%) 1 (2%) 1 (1%) 
  Treatment record total n 65 61 126 
Adherence Questionnaireb     
    Forgot/lack of support n (%) 10 (29%) 10 (30%) 20 (30%) 
    Ran out of drug n (%) 8 (24%) 9 (27%) 17 (25%) 
    Problems taking some of the  
      drugs (e.g., intolerance,  
      taste, medication volume) 
n (%) 11 (32%) 5 (15%) 16 (24%) 
    Fear of disclosure to others n (%) 10 (29%) 5 (15%) 15 (22%) 
    Patient refused/didn’t want  
      to take drugs 
n (%) 10 (29%) 4 (12%) 14 (21%) 
    Scheduling/lifestyle  
      interference 
n (%) 9 (26%) 3 (9%) 12 (18%) 
    Drug toxicity concerns n (%) 7 (21%) 4 (12%) 11 (16%) 
    Supervised by someone else  
      or multiple caregivers 
n (%) 6 (18%) 5 (15%) 11 (16%) 
    Patient unwell n (%) 6 (18%) 4 (12%) 10 (15%) 
    Other n (%) 4 (12%) 5 (15%) 9 (13%) 
    Different routine/change in  
      living situation 
n (%) 3 (9%) 4 (12%) 7 (10%) 
    Fed up giving/taking drugs n (%) 3 (9%) 2 (6%) 5 (7%) 
    Think medication is not  
      needed or not helping 
n (%) 2 (6%) 2 (6%) 4 (6%) 
    Caregiver unwell/depressed n (%) 0 (0%) 0 (0%) 0 (0%) 
  Total listed problems on 
questionnaireb 
n 89 62 151 
  Total participants with 
questionnaire- 
    reported missed doses 
n 34 33 67 
Total Treatment Disruption Eventsc n 97 94 191 
Abbreviations: n, subsample size or number of events; NNRTI=non-nucleoside reverse transcriptase inhibitor; 
PI=protease inhibitor. 
a One category allowed per treatment record change or stop. 
b Participants may have answered in more than one category.  
c Some participants had both a treatment record and adherence questionnaire event at the same time.
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CHAPTER 5: PER-PROTOCOL EFFECT OF PROTEASE INHIBITOR VERSUS NON-
NUCLEOSIDE REVEERSE TRANSCRIPTASE INHIBITOR REGIMENS IN 
CHILDREN LIVING WITH HIV 
A. Overview 
Adherence to antiretroviral therapy predicts outcomes of pediatric antiretroviral therapy. 
We aimed to estimate the per-protocol effect of initial protease inhibitor versus non-nucleoside 
reverse transcriptase inhibitor-based antiretroviral therapy in treatment-naïve children living with 
HIV in developed countries in a setting of ideal adherence. We used data from the PENPACT-1 
trial, which randomized children to initial therapy with either of these regimens starting in 2002 
and followed until the last enrollee reached 4 years of follow-up in 2009. We performed an 
intention-to-treat analysis to estimate time to treatment failure. Then we generated per-protocol 
estimates by administratively right-censoring participants who experienced non-medically 
indicated treatment disruption or dropout and used inverse-probability of censoring weights to 
correct for imparted informative censoring. In the intention-to-treat analysis, participants on 
protease inhibitors experienced a 4-year probability of treatment failure of 41.3% versus 39.5% 
for participants on non-nucleoside reverse transcriptase inhibitors with a risk difference of 1.8% 
and hazard ratio of 1.09 (95% CI 0.74-1.60). Protocol deviations were non-differential across 
arms. In the per-protocol analysis, participants on protease inhibitors experienced treatment 
failure probability of 35.5% versus 29.5% in the non-nucleoside reverse transcriptase inhibitor 
arm for a 4-year risk difference of 6.4% and hazard ratio of 1.30 (95% CI 0.80-2.12). Shifts in 
failure probabilities from the intention-to-treat to per-protocol analysis were 5.7% in the protease 
inhibitor arm versus 10.3% in the non-nucleoside reverse transcriptase arm. Inverse probability 
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of censoring weights provided clinically meaningful insights into the influence of adherence on 
clinical outcomes. For children living with HIV in developed countries, in a setting of unknown 
adherence, either protease inhibitor or non-nucleoside reverse transcriptase inhibitor initial 
therapy may be comparable, but if adherence may be ensured, then an initial NNRTI regimen 
may prove superior for durable viral suppression. 
B. Introduction 
Adherence is critical to success of antiretroviral therapy (ART) in children living with 
human immunodeficiency virus (HIV). The sentinel data in adults found that a mere 10% 
decrease in adherence was associated with a doubling of HIV RNA viral load,32,34 and treatment 
failure on ART with an unboosted protease inhibitor (PI) increased greatly with adherence 
<95%.33 Continuous and optimal administration of ART decreases viral load, which decreases 
the probability of HIV sub-populations acquiring antiretroviral resistance mutations,5,35 
preserving the longevity of current and future ART regimens,113 as well as decreasing chances of 
forward infection.114 Unfortunately, ART appears to be less successful in producing viral 
suppression in children,21 who may require more potent regimens to achieve suppression.5 
Children are also more prone to acquiring antiretroviral resistance mutations due to higher 
plasma viral loads, allowing more spontaneous mutations; less robust antiviral immune 
responses; pharmacokinetic challenges with concomitant requirements for more frequent dosing; 
and social and behavioral dependency.5 Moreover, adherence challenges increase into and 
through adolescence, with concomitantly worse viral and immunological outcomes.22-25,115 
Poor adherence may also complicate assessment of ART efficacy in clinical trials. Early 
HIV studies estimated modest average adherence around 70%,36-39 especially among those who 
failed to achieve viral suppression,40 and even successful clinical trials were only able to attain 
about 80% adherence.124,125 The intention-to-treat (ITT) parameter estimates the effect of being 
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assigned to a treatment protocol. In standard ITT analysis of clinical trials, poor adherence 
typically biases estimates of effective treatments towards the null, resulting in under-estimation 
of treatment efficacy and over-estimation of treatment safety.102,126,127  
 The per-protocol parameter estimates the effect of being assigned to, and remaining on, a 
treatment protocol. Robins and Finkelstein (RF) introduced inverse probability of censoring 
weights (IPCW) to account for non-indicated treatment disruptions, whether by stoppage or 
switching of assigned therapy, or by study dropout; and describe a consistent estimator of the 
per-protocol effect.95 This RF approach administratively censors study participants who cease to 
follow the assigned protocol, for instance, stopping or switching medications for reasons other 
than medical indications, such as adverse events. The approach then up-weights similar 
participants remaining under study to correct for induced informative censoring. The RF 
approach has been shown to uncover previously underpowered treatment differences,95 correct 
for bias towards the null inherent in ITT analysis,88 and estimate the effect of potentially 
preventable treatment discontinuations.128 The RF provides a principled way to address 
problematic post-randomization protocol violations, such as poor adherence and study dropout, 
which may affect clinical trial results.64 
 We apply the RF approach to the PENPACT-1 (PENTA 9 / PACTG 390) trial, which 
randomized treatment-naïve children living with HIV-1 to ART with either a PI or a non-
nucleoside reverse transcriptase inhibitor (NNRTI).45 This trial has only previously been 
analyzed using ITT approaches, which yielded null results. Certain PI characteristics decrease 
adherence and tolerability, particularly in children: poor taste; gastrointestinal toxicity; and 
regimen complexity, such as pill burden, storage requirements, and dosing frequency.18-
20,37,41,60,110 However, boosted PI-based regimens appear more forgiving of treatment disruptions 
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than do NNRTI-based regimens.55,57,60,96,98 We hypothesized that the null result of the ITT 
analysis may have resulted from a cancellation effect: Worse adherence to PIs cancelled their 
more robust efficacy. Therefore, we aimed to apply the RF approach to evaluate the per-protocol 
effect of initial PI- vs. NNRTI-based ART on time to treatment failure in treatment-naïve 
children living with HIV in a setting of ideal adherence. 
C. Methods 
C1. Study Design 
PENPACT-1 (PACTG 390 / PENTA 9) was an international multicenter phase 2/3, 
randomized, open-label trial enrolling children infected with HIV-1 from 68 clinical centers in 
13 countries in Europe and North and South America between September 25, 2002, and 
September 7, 2005.45 Eligible children aged 31 days to less than 18 years were HIV-1-infected 
and had not received ART or only received antiretrovirals for <56 days to reduce mother-to-child 
transmission (excluding single-dose nevirapine). All parents or guardians and children, as 
appropriate, gave written consent for the parent trial; this protocol was approved by the relevant 
ethics committee or institutional review board (IRB) for each participating center. The per-
protocol analysis was approved by IRBs at Duke University, University of North Carolina-
Chapel Hill, and Children’s Mercy Kansas City. This study is registered with the International 
Standard Randomised Controlled Trial Number Registry (ISRCTN73318385). 
Children were randomized 1:1 to start ART with two nucleoside reverse transcriptase 
inhibitors (NRTIs) plus either a PI or an NNRTI. The study was open label, and the treating 
clinician chose the two NRTI drugs combined with a drug from the randomly assigned PI or 
NNRTI class. Children underwent clinical and HIV-1 RNA viral load assessments at 
randomization (week 0), weeks 2, 4, 8, 12, 16, 24, and then every 12 weeks until the last child 
assigned to treatment reached 4 years of follow-up (August 31, 2009). Treatment starts, changes, 
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and stoppages were recorded at clinical visits and ad hoc throughout the study, along with 
reasons for the medication change. Trained study personnel administered validated adherence 
questionnaires every 24 weeks after randomization.61 Adherence questionnaires recorded the 
number of missed doses to all antiretrovirals over the 3 days prior to visit. Four years of follow-
up was defined as the week 204 visit plus a 6-week lag to capture late visits. Participants were 
followed until their last documented viral load, viral failure, or 4 years, whichever occurred first. 
C2. Protocol Deviations 
Protocol deviations were defined as any non-medically indicated stoppages or changes of 
any component of the initially prescribed ART regimen that resulted in the participant receiving 
fewer than two NRTIs or not receiving the assigned class of PI or NNRTI at any time. The 
assigned class of PI or NNRTI on first line ART must have been according to randomized arm; 
the assigned class on second line ART must have been the reverse of the originally randomized 
class. Any switch to a third line or other regimen was considered a protocol deviation. 
Participants receiving both a PI and an NNRTI at the same time or use of other classes, such as 
integrase inhibitors or fusion inhibitors, were defined as protocol deviations, regardless of the 
reason for the prescription change.   
ART medication stoppages or changes were captured from both treatment records and 
adherence questionnaires. From treatment records, we defined medically indicated reasons for 
ART stoppages or changes as adverse events, viral failure, resistance, death, pregnancy, regimen 
simplification, or medication switches within the same antiretroviral class. During the study, 
nelfinavir underwent a drug recall. Any immediate switch to another drug within the same class 
for a nelfinavir recall or other drug supply problem was defined as a non-protocol deviation, but 
any interruption of ART or switch to another drug class was defined as a protocol deviation, as 
other drugs within the same class should have been available. 
 
65 
Because a medically indicated reason for ART stoppage or change would require a 
clinician to determine the indication, any missed dose reported on the adherence questionnaire, 
regardless of reason, was defined as a non-medically indicated stoppage. Study dropout, defined 
as cessation of viral load measurements before 4 years on study, was counted as a protocol 
deviation. All non-medically indicated ART stoppages or changes and all dropouts were defined 
as protocol deviations at their first occurrence.  
C3. Study Outcome 
Our primary outcome was time to viral failure or clinical failure within 4 years of 
randomization. Time to viral failure was defined at the first of two consecutive viral loads >400 
copies/mL at or after Study Week 24 (≥20 weeks after randomization). Because the protocol 
only required viral load confirmation of viral failure at higher viral loads (>1,000 copies/mL or 
>30,000 copies/mL) and other factors leading to missed viral load measurements (such as 
dropout, not returning for labs, and protocol deviations), many viral loads >400 copies/mL were 
not confirmed within a short time frame. Thus, we used the next measured viral load value, 
regardless of time interval, to confirm viral failure.  
Clinical failure was defined as clinical disease progression, namely a new Centers for 
Disease Control and Prevention (CDC) stage C event (generally equivalent to a CDC stage 3 
clinical event in the 2014 staging guidelines),103,104 or other clinical progression such that the 
treating clinician believes that changing therapy was required prior to reaching the viral load 
switch point. Time to clinical failure was defined at documentation of the event in the treatment 
record or case report form. 
C4. Covariates 
Time-fixed covariates included age at enrollment (<3 vs. 3-17 years), exposure to 
perinatal antiretrovirals, research network/region (PACTG/IMPAACT vs. PENTA), route of 
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HIV exposure (vertical vs. other), baseline CDC clinical staging (stage C or not, categorized by 
the 1994 revised CDC classification system, as used by the parent study), baseline CD4 cell 
count (stage 1 vs. 2 or 3, categorized according to 2014 CDC immunologic criteria),104,129,130 and 
baseline log10 viral load. Time-varying covariates included most recent categorized CD4 cell 
count from the prior visit, most recent log10 viral load from the prior visit, and an ART switch 
indicator variable. New HIV-related clinical manifestations on ART were not included because 
they were rare. Covariates were selected based on subject-matter knowledge and reduced to the 
strongest predictors of both censoring and treatment failure to ensure model convergence. The 
final reduced IPCW model included baseline clinical staging, baseline log10 viral load, time-
varying categorized CD4 cell count, time-varying log10 viral load, and time since randomization. 
Variable coding was defined according to CDC staging, trial definitions, and exploration 
of data fit by splines and polynomial expansion. Time since randomization was coded using a 
restricted quadratic spline, whereas baseline viral load and time-varying viral load fit linear and 
quadratic relationships on the logit scale. 
C5. Statistical Analysis 
We contrasted PI vs. NNRTI treatment arms as randomized in the parent study’s 
modified ITT analysis, which included only participants who started ART. First, we performed 
an unweighted analysis of the original data to generate modified ITT estimates. The sole 
modification was removal of three participants: two who withdrew consent prior to ART 
initiation, and one with a major eligibility violation (Figure 5.1). Follow-up began at the date of 
randomization. Participants were right-censored at dropout or 4 years on study.  
Then we applied IPCW to estimate the per-protocol effect. Any participant who 
experienced a protocol deviation was right-censored (Figure 5.1). Then, we applied IPCW to 
correct for imparted informative censoring. IPCW were calculated separately for each treatment 
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arm. For each arm, we fit a pooled logistic regression to estimate the probability of not being 
censored for protocol deviations using baseline and time-varying covariates for each participant 
at each week under study. This probability was applied as the denominator of the IPCW, and 
time on randomization was applied as the numerator to stabilize the weights. If time-varying 
values were missing, we carried forward the last observed value. Participants remaining under 
study were up-weighted, using the inverse of the probability of remaining free from a protocol 
deviation, to replace an equivalent number of participants who were censored. Censoring and up-
weighting were applied cumulatively at the week of each protocol deviation until the end of 4 
years on study. Similar to the modified ITT analysis, follow-up began at randomization, and 
participants were right-censored without up-weighting at 4 years on study. 
We used descriptive statistics to characterize baseline covariates in the study sample. For 
the primary outcome, we estimated the risk of viral failure using the complement of the Kaplan-
Meier estimator, unweighted for modified ITT analysis and applying IPCW for the per-protocol 
analysis. We estimated the hazard ratio (HR) for viral failure using a Cox proportional hazards 
model, unweighted and weighted. Proportional hazards assumptions were assessed graphically 
and using time interaction terms. In adjusted analyses, the ITT analysis was stratified by baseline 
randomized stratification variables: age, exposure to perinatal antiretrovirals, and research 
network (which varied by region). For the per-protocol analysis conditional on randomized 
stratification variables, we added the randomized stratification variables to the final reduced 
model for IPCW. All confidence intervals were estimated using the robust sandwich variance 
estimator.   
Finally, we assessed the sensitivity of our results to changes in our model specifications. 
Given the relation between time-varying viral load from the prior visit and viral failure, an 
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alternative IPCW model excluded time-varying viral load. Other alternative IPCW models 
excluded the weakest predictor of censoring and outcome (baseline CDC clinical staging) and 
included only randomized stratification variables. Sensitivity analyses assessed the extremes of 
corrections for censoring protocol deviations by (1) estimating effects without applying IPCW; 
(2) assuming all censored participants in the PI arm were failures and all censored participants in 
the NNRTI arm were non-failures; and (3) reversing this latter coding.   
Analyses were conducted in SAS® version 9.4 (Cary, NC). 
D. Results 
 PENPACT-1 enrolled 266 HIV-1 infected children from 68 centers in 13 countries in 
Europe, North America, and South America. The modified ITT analysis was restricted to 263 
participants who initiated ART. Participants were a median age of 6.5 years at enrollment (IQR 
[interquartile range], 1.8-12.9), 52% male, 49% black, and 79% exposed to HIV via vertical 
transmission (Table 5.1). Nineteen percent had severe clinical symptoms (CDC stage C). Median 
growth parameters were below average (weight-for-age Z score -0.6; height-for-age Z score -
0.9). Median CD4 Z-score was -3.5, consistent with predominance of moderate to severe 
immunosuppression, and median viral load was 5.0 log10 copies/mL. Whereas 15% of children 
had antiretroviral exposure for prevention of mother-to-child transmission, 4% had at least one 
major resistance mutation at baseline. Baseline characteristics relating to mode of HIV-1 
acquisition, clinical and immunological status, and ART resistance were generally balanced 
across ART regimens. 
 One hundred four participants (PI 53, NNRTI 51) experienced treatment failure by 4 
years, of which 103 were viral failures and one was clinical progression despite ART. One 
participant died of HIV-related complications while on study but after the 4-year primary end 
point. In the ITT analysis, participants on PI regimens experienced a 4-year probability of 
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treatment failure of 41.3% vs. 39.5% for participants on NNRTI regimens for a 4-year risk 
difference (RD) of 1.8% and HR 1.09 (95% CI 0.74-1.60) [Figure 5.2, Table 5.2]. When 
stratified on randomized stratification variables, 4-year failure probabilities decreased to 34.8% 
and 32.6% for PI and NNRTI arms respectively, but the RD (2.2%) and HR (1.10, 95% CI 0.75-
1.62) remained similar to the unadjusted ITT analysis. 
 Protocol deviations were frequent in the dataset. By 4 years, 118 participants were 
censored for any protocol deviation, of which 57 were from the PI arm and 61 were from the 
NNRTI arm (Table 5.3). Of these protocol deviations, 108 were due to non-medically indicated 
treatment disruptions (PI 55, NNRTI 53), 14 were due to dropout (PI 5, NNRTI 9), and four 
experienced both events in the same week (PI 3, NNRTI 1). Although non-medically indicated 
treatment disruptions were common and reported slightly more frequently in PI over NNRTI 
arms (RD 2.4%, HR 1.09 [95% CI 0.75-1.59]), dropout occurred less often in PI than NNRTI 
arms (RD -2.6%, HR 0.82 [0.33-2.07]) and much less frequently across arms than non-medically 
indicated treatment disruptions (Figure 5.3). Combining these two sources of protocol deviations 
yielded estimates of censoring that were generally balanced between PI and NNRTI arms (RD -
2.2%, HR 0.98 [95% CI 0.68-1.40]. When stratifying on randomized stratification variables, all 
protocol deviation categories shifted mildly toward PI arm deviations.  
 In the per-protocol analysis, participants on PI regimens experienced a 4-year probability 
of treatment failure of 35.5% vs. 29.5% for participants on NNRTI regimens for a 4-year RD of 
6.4% and HR 1.30 (95% CI 0.80-2.12) [Table 5.2]. These failure probabilities were lower than 
the ITT analysis, consistent with censoring of participants having protocol deviations prior to 
treatment failure (Figure 5.2). IPCW weights in the primary per-protocol analysis were centered 
near one with mean 0.981, median 0.988, minimum 0.550, maximum 1.969. When randomized 
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stratification variables were included in the IPCW model, 4-year failure probabilities changed to 
39.4% and 30.5% for PI and NNRTI arms respectively, and RD (8.9%) and HR (1.41, 95% CI 
0.85-2.35) were greater than the primary per-protocol analysis. 
 Shifts in treatment failure probability between ITT and per-protocol primary analyses 
were smaller for the PI arm than the NNRTI arm. Comparing ITT to per-protocol analyses, PI 
failure probability at 4 years decreased from 41.3% to 35.6% for a difference of 5.7% (Table 
5.2). The ITT to per-protocol comparison in the NNRTI arm resulted in a 4-year failure 
probability shift from 39.5% to 29.2% for a difference of 10.3%. Cross-wise comparisons of 
treatment failure probabilities in the per-protocol PI arm (35.6%) versus the ITT failure 
probability of the NNRTI arm (39.5%) favored the PI arm by a difference of -3.9%.  
Alternative model specifications did not change results substantially (Table 5.4). 
Sensitivity analysis estimating the probability of treatment failure in the setting of censoring for 
protocol deviations without IPCW correction yielded an RD of 5.1% and HR of 1.24 (95% CI 
0.76-2.01) [Figure 5.4]. The extreme bound of censoring corrections that assumed all censored 
PI participants failed and no NNRTI participants failed yielded an RD 45.4% and HR 4.23 (95% 
CI 2.78-6.45). Reversing this coding for the other extreme bound yielded an RD of -40.6% and 
HR 0.30 (0.20-0.45). Therefore, the IPCW correction added information over censoring alone 
but was well within extreme bounds, suggesting that the per-protocol estimates were within 
reasonable limits of plausibility. 
E. Discussion 
 Using data from the PENPACT-1 study, we generated ITT estimates followed by per-
protocol estimates using the RF-IPCW approach to account for the influence of protocol 
deviations related to non-indicated treatment disruptions and dropouts. Consistent with the 
results of the parent study,45 our ITT estimates were close to the null. However, when 
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administratively right-censoring for these protocol deviations and correcting for imparted 
informative censoring by using IPCW, the per-protocol estimates demonstrate a clinically 
meaningful shift in effect estimates, albeit imprecise. These PENPACT-1 per-protocol estimates 
are similar to those of adult clinical trials comparing ART classes that concluded regimen 
superiority of integrase strand transferase inhibitors (INSTIs). For example, phase 3 randomized 
controlled trials concluded superiority of dolutegravir-based regimens over efavirenz and 
ritonavir-boosted darunavir regimens at risk differences of 7%.119,131 These results led to the 
elevation of INSTIs to preferred initial regimens for adolescents and adults in U. S. Department 
of Health and Human Services (DHHS) and World Health Organization (WHO) treatment 
guidelines.132,133 Although pediatric studies are necessarily of smaller size, based on the 
conclusions of adult data, we suggest that the PENPACT-1 per-protocol estimates represent 
clinically significant results. Therefore, we suggest that pediatric PI regimens may be more 
robust against adherence lapses, but NNRTI regimens may have better efficacy for children in 
developed countries in settings of ideal adherence. 
 The shift between ITT and per-protocol parameter estimates lends credence to our a 
priori hypothesis that PIs are more robust against adherence lapses than NNRTIs. Non-
adherence is a major driver of differential treatment failure in the PENPACT-1 trial, with a lower 
influence in the PI arm than the NNRTI arm. The RF-IPCW method comprises two components: 
(1) the relationship between treatment arm and censoring for protocol non-adherence and (2) the 
relationship between censoring for non-adherence and treatment failure. The relationship 
between treatment arm and censoring for protocol non-adherence is illustrated in Figure 5.3, 
where the curves for protocol deviations overlap between PI and NNRTI regimens, indicating 
non-differential protocol non-adherence across arms. Thus, the differential shift in treatment 
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failure curves from Figure 5.2A (ITT analysis) to Figure 5.2B (per-protocol analysis) derives 
principally from the remaining relationship between protocol non-adherence and treatment 
failure. The magnitude of downward shift from ITT to per-protocol curves represents failures 
attributable to non-adherence. These failures attributable to non-adherence were smaller in the PI 
arm than the NNRTI arm, with an associated smaller shift in PI (~6%) failure probabilities than 
NNRTIs (~10%) when estimating ITT vs. per-protocol 4-year failure risks. Since this larger shift 
moves the PI vs. NNRTI comparisons from essentially a null result in the ITT analysis to a 
clinically meaningful difference in the per-protocol analysis, we suggest that treatment failures in 
the PI arm were less influenced by non-adherence than NNRTIs. 
 Other studies comparing PI to NNRTI regimens had variable results, depending on study 
design, setting, and population. Similar to PENPACT-1, inadequate adherence in the 
NEVEREST study had less influence on viral outcomes in children continuing a ritonavir-
boosted lopinavir regimen (LPV/r) than children switching to nevirapine,99 and shifts in viral 
failure between the ITT and per-protocol analyses of the pediatric PROMOTE study were 
smaller in the LPV/r than nevirapine arm and of similar magnitude to PENPACT-1.121 In 
contrast, 5-year RF-IPCW per-protocol outcomes in IMPAACT P1060 increased the rate ratio 
for treatment failure or death over the ITT HR in nevirapine versus to LPV/r-regimens.84,100 
Adult studies have estimated the adherence level required for viral suppression on unboosted and 
boosted PIs may be higher than for NNRTI regimens, but PIs are less prone to developing 
resistance at similar levels of adherence.39,54,56,134-137  
 As a secondary observation, the PENPACT-1 per-protocol results raise the possibility 
that initial NNRTI therapy may be superior to PIs for children in developed countries in the 
setting of ideal adherence. Although PIs and NNRTIs were comparable when non-adherence was 
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allowed in the ITT setting, the per-protocol analysis generated a clinically meaningful difference 
in viral failure under the counterfactual scenario of perfect adherence, as measured by the study. 
Although such a scenario is idealized, with greater accuracy in predicting adherence and better 
prescribing to an appropriate regimen, the more we expect that realized results would move 
towards the per-protocol estimate. At the extreme, perfect assignment of adherers to NNRTIs 
and mixed assignment of adherers and non-adherers to PIs, we might expect a 4-year contrast of 
the per-protocol NNRTI failure risk (29%) to the ITT PI risk (41%).  
 This consideration of expected outcomes under different scenarios of adherence 
supplements the variable results from pediatric clinical trials comparing PI and NNRTI-based 
regimens.101 In IMPAACT P1060, children on LPV/r experienced less viral failure or treatment 
discontinuation with a 24-week risk difference of 21.5%.100 Compared with PENPACT-1, P1060 
participants were from developing countries and generally higher risk: younger ages, higher viral 
loads, lower CD4%, lower weight-for-age z-scores, and more advanced or severe WHO 
classifications. Moreover, potential reasons for LPV/r superiority may have been the higher viral 
loads in younger ages, with resulting greater difficulty in achieving viral suppression and higher 
risk of acquired resistance on nevirapine therapy, and use of half-dose strategy for the first 2 
weeks of nevirapine, which may have resulted in suboptimal nevirapine concentrations at a time 
when viral load was most elevated. Such explanations are consistent with most nevirapine 
failures occurring early in the study, then stabilizing and persisting for up to 5 years afterwards.84 
In contrast, the PROMOTE study had comparable results to PENPACT-1 with Kaplan-Meier 
viral failure risk difference at 96 weeks of 2%.121 PROMOTE enrolled older children up to 6 
years in age with more use of efavirenz in children over 3 years old. Adult data from the 
Democratic Republic of Congo have also concluded similarity in treatment failure between 
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LPV/r and nevirapine, although a per-protocol analysis demonstrated more viral failure with 
nevirapine.138 
 A major difference in the PENPACT-1 data from other similar pediatric trials is the 
heterogeneity of ART regimens. In PENPACT-1, 62% of participants in the NNRTI arm were 
started on efavirenz,45 which generally has better a better toxicity and tolerability profile than 
nevirapine and does not involve the ramp-up dosing phase. About half of the enrollees of the PI 
arm of this study were started on an unboosted PI (nelfinavir), while most of the rest were started 
on a boosted PI (LPV/r). Then, most participants started on nelfinavir were switched mid-study 
to a boosted PI because of a nelfinavir recall. Even the nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs) were heterogenous, as the treating clinicians chose the specific 
backbones. PENPACT-1 was designed to assess an initial treatment strategy, rather than specific 
regimen comparisons. However, within-class heterogeneity may have influenced results. 
Efavirenz-based regimens may have greater viral efficacy for children in developing countries.139 
Whereas the NEVEREST trial identified more confirmed viral failure >1,000 copies/mL for 
nevirapine compared to LPV/r,99 a similar trial using efavirenz performed more favorably with 
lower point estimates for viral failure after switching to efavirenz and overall non-inferiority of 
efavirenz to LPV/r.140 In an adult trial, LPV/r had better viral efficacy and lower resistance than 
nelfinavir.58,59  
An alternative explanation of our observed ITT to per-protocol shift may be that 
participants on PIs experienced more medically indicated treatment disruptions that led to viral 
failure. Our method only censored and corrected for non-medically indicated treatment 
disruptions and dropouts, as medically indicated treatment disruptions, such as adverse events or 
pregnancy on a regimen with potential teratogenicity, would have been appropriate medical care. 
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If PIs and NNRTIs lead to differential medically indicated treatment switches or stoppages, 
which then lead to differential treatment failure, such would also lead to a separation of treatment 
failure curves. However, additional analysis of treatment disruptions in the PENPACT-1 data 
indicated that although PIs may be more difficult to tolerate, the most frequent reasons 
documented for treatment disruptions were events common to the classes, such as forgetting to 
take the medications, and overall treatment disruptions were comparable across PI and NNRTI 
arms. 
Of note, most treatment failures occurred early in the study, most frequently by week 24. 
PENPACT-1 adherence questionnaires did not start until the week 24 visit, and viral failure 
events were only defined starting at week 24; although at 24 weeks, treatment disruptions 
between 0 and 24 weeks were recorded.  
 Finally, our strongest limitation is measurement error. Measurements of adherence were 
based on the study’s treatment records, which note prescriptions and treatment events, and 
adherence questionnaires that may be prone to reporting biases. Direct measurements of drug 
concentrations in plasma, peripheral blood mononuclear cells, hair, or urine would have been 
preferable.101,141-143  
F. Conclusion 
 In conclusion, reanalysis of the PENPACT-1 study using the RF-IPCW method provided 
clinically meaningful insights into the influence of adherence and dropout on clinical outcomes. 
Children living with HIV in developed countries may experience less of an influence of 
adherence on viral failure outcomes if assigned to initial PI therapy, but under conditions of ideal  
adherence, NNRTI regimens may lead to better viral outcomes. As a result, in a setting of   
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unknown adherence, either PI or NNRTI initial therapy may be comparable, but if adherence 















Figure 5.2. Risk of treatment failure over 4 years by treatment arm by (A) intention-to-treat analysis and (B) per-protocol 
analysis. The dotted line represents initial PI-based ART, and the solid line represents initial NNRTI-based ART. ART: antiretroviral 









Figure 5.3. Risk of protocol deviation over 4 years by treatment arm. Panels represent proportion of children with (A) non-
indicated treatment disruption, (B) dropout, and (C) any protocol deviation by 4 years, comparing initial ART with a PI vs. an NNRTI. 
The dotted line represents initial PI-based ART, and the solid line represents initial NNRTI-based ART. ART: antiretroviral therapy; 




Figure 5.4. Risk of treatment failure over 4 years by treatment arm by censoring for 
protocol deviations without upweighting. The dotted line represents initial PI-based ART, and 
the solid line represents initial NNRTI-based ART. ART: antiretroviral therapy; NNRTI: non-





Table 5.1. Baseline characteristics of study participants according to initial ART regimen. 
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range; N, total sample size; n, subsample size; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. 
a PENTA sites were predominantly in Europe, South America, and the Bahamas. PACTG/IMPAACT sites were 
based primarily in the United States. 
b Not all patients had successful baseline genotypic resistance assays.  
  
  Randomized Group 
Variable  PI NNRTI Total 
N  131 132 263 
Age  
  <3 years       
  3-17 years           
















6.5 (2.8, 12.9) 
Sex 










  Black, Non-Hispanic     
  White, Non-Hispanic    


















  PENTA                   













Route of Infection 
  Vertical 













CDC Clinical Stage 
  N or A or B 













Weight-for-Age Z-score Median (IQR) -0.5 (-1.6, 0.1) -0.7 (-1.6, 0.2) -0.6 (-1.6, 0.1) 
Height-for-Age Z-score Median (IQR) -0.9 (-1.5, -0.2) -0.9 (-1.8, 0) -0.9 (-1.7, -0.2) 
CD4 Z score Median (IQR) -3.6 (-7.2, -1.7) -3.4 (-6.5, -1.4) -3.5 (-6.8, -1.6) 
Viral Load log10 copies/mL Median (IQR) 5.1 (4.5, 5.7) 5.0 (4.5, 5.6) 5.0 (4.5, 5.7) 
Perinatal Antiretroval Exposure n (%) 19 (15%) 20 (15%) 39 (15%) 
≥1 Major Resistance Mutationb n/N (%) 5/116 (4%) 5/123 (4%) 10/239 (4%) 
HIV-1 subtype 
  B 
  C 
  F 
  A/CRF_AG/D/G 


























  1,000 copies/mL    





























at 4 years 
Hazard Ratio  
(95% CI) 
Primary Analyses     
    Intention-to-treat (ITT) analysis 41.3% 39.5% 1.8% 1.09 (0.74-1.60) 
    Per-protocol (PP) analysis 35.6% 29.2% 6.4% 1.30 (0.80-2.12) 
Conditional on Randomized  
  Stratification Variables 
    
    ITT with stratification on  
      randomized stratification  
      variables 
34.8% 32.6% 2.2% 1.10 (0.75-1.62) 
    PP with censoring and IPCW  
      including randomized  
      stratification variables  
39.4% 30.5% 8.9% 1.41 (0.85-2.35) 
Abbreviations: CI=confidence interval; IPCW=inverse-probability of censoring weights; ITT=intention-
to-treat; NNRTI=non-nucleoside reverse transcriptase inhibitor-based regimen; PI=protease inhibitor-




























52.0% 49.7% 2.4% 1.09 (0.75-1.59) 1.21 (0.84-1.76) 
Dropout 7.8% 10.4% -2.6% 0.82 (0.33-2.07) 0.86 (0.35-2.13) 
Any Protocol Deviation 
(Non-Indicated 
Disruption or Dropout) 
52.9% 55.1% -2.2% 0.98 (0.68-1.40) 1.09 (0.76-1.57) 
Abbreviations: CI=confidence interval; NNRTI=non-nucleoside reverse transcriptase inhibitor-based 













at 4 years (%) 
Risk 
Difference 
at 4 years 
Hazard Ratio  
(95% CI) 
Alternative Models     
  PP with censoring for protocol  
    deviations and IPCW model  
    without time-varying viral load 
33.7% 28.6% 5.2% 1.25 (0.77-2.03) 
  PP with censoring for protocol  
    deviations and IPCW model  
    without time-varying viral load  
    and baseline clinical stage 
34.2% 28.5% 5.7% 1.26 (0.77-2.05) 
  PP with censoring for protocol  
    deviations and IPCW model  
    with time-varying viral load  
    without baseline clinical stage 
36.0% 29.4% 6.6% 1.30 (0.80-2.12) 
  PP with censoring for protocol 
    deviations with IPCW using  
    only randomized stratification  
    variables and time on study  
34.0% 29.4% 4.6% 1.22 (0.74-2.00) 
Sensitivity Analyses     
  PP with censoring for protocol  
    deviations (without IPCW) 
33.5% 28.4% 5.1% 1.24 (0.76-2.01) 
  PP with censoring and single  
    imputation (all censored PIs as  
    failures and all censored  
    NNRTIs as non-failures) 
68.0% 22.6% 45.4% 4.23 (2.78-6.45) 
  PP with censoring and single  
    imputation (all censored PIs as  
    non-failures and all censored  
    NNRTIs as failures) 
26.4% 67.0% -40.6% 0.30 (0.20-0.45) 
Abbreviations: CI=confidence interval; IPCW=inverse-probability of censoring weights; NNRTI=non-









CHAPTER 6: CONCLUSION 
A. Overview 
 We aimed to examine the effects of treatment regimen, protocol non-adherence, and 
treatment failure in our analysis of the PENPACT-1 trial. Although the parent trial found a null 
effect of initial PI vs. NNRTI-based ART, we hypothesized that this null result was due to 
canceling effects of protocol non-adherence and regimen potency. Specifically, we hypothesized 
that PIs would have worse time to treatment disruption but be more robust against treatment 
failure in the setting of protocol non-adherence. Our hypothesis was wrong.  
In Aim 1, we assessed randomized initial PI vs NNRTI-based ART in children for 
differences in treatment disruption at 4 years after randomization and end of study. PIs and 
NNRTIs had similar time to treatment disruption, although the PI class appeared to result in 
greater reported intolerance. Despite this greater intolerance, the most common reasons for 
treatment disruption were common to both regimens, such as forgetting to take the medications, 
and participants persisted in ingesting the both regimens despite differences in tolerability.  
In Aim 2, we performed an ITT analysis of initial PI vs. NNRTI-based ART on time to 
treatment failure by 4 years after randomization. Then, we performed a per-protocol analysis 
applying the RF-IPCW method to administratively right-censor participants at the time they 
experienced a protocol deviation, then upweight similar participants remaining in the study to 
correct for possible imparted informative censoring. The ITT analysis yielded estimates close to 
the null. The per-protocol analysis yielded estimates favoring initial NNRTI-based ART with 
lower 4-year treatment failure probability, indicating possibly better potency of initial NNRTI-
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based therapy in the setting of ideal protocol adherence. Further, initial PI-based ART had a 
smaller shift in estimates from the ITT to per-protocol estimates, indicating greater robustness 
against the effects of protocol non-adherence.  
Thus, our overarching hypothesis was disproven, and the explanation was contrary to our 
initial reasoning. Treatment disruption was similar between arms, meaning that that protocol 
non-adherence was not a differential contributor to the regimen effects under study. Instead, the 
cancelation effect observed in PENPACT-1 appears to result from canceling effects of regimen 
potency and robustness. Specifically, NNRTI-based regimens appear to have greater treatment 
potency (lower treatment failure probability) than PI-based ART in the setting of ideal ART 
protocol adherence, but NNRTI’s appear to be more prone to influences of non-adherence. 
Because non-adherence led to a greater shift in treatment efficacy in NNRTIs than in PIs, the 
NNRTI treatment failure curved moved more than the PI curve in the setting permissive of non-
adherence such that the treatment failure curves equalized. In other words, regimen potency and 
robustness canceled. 
A1. Aim 1 Summary of Key Findings 
 In Aim 1, we investigated the relationship between treatment regimen and time to 
treatment disruption. Our essential question was whether prescribing a PI or NNRTI-based initial 
ART would affect the time a child may maintain optimal, uninterrupted first-line therapy. To this 
aim, we analyzed the PENPACT-1 data, which randomized children aged 31 days to <18 years 
to initial ART with two NRTIs plus a PI or an NNRTI. We analyzed the same modified ITT 
population as the parent trial to assess time to the participant’s first treatment disruption event, 
using participant treatment records and adherence questionnaires. Participants were followed 
until the primary study endpoint of 4 years after randomization and at end of study. We analyzed 
the data using the complement of the Kaplan-Meier and Cox proportional hazards models. 
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 The large majority of participants (>70%) experienced at least one treatment disruption 
during the study. At 4 years, 7% more participants randomized to initial PI-based regimens 
experienced a treatment disruption event than participants randomized to initial NNRTI-based 
ART. By the end of study, differences in time to treatment converged. Overall hazard ratios were 
close to the null, and confidence intervals were wide given the modest study size. 
 On exploration of reasons for treatment disruption, PI regimens appeared to have greater 
problems with tolerability, such as adverse events, problems taking the medications, and refusal 
to take the drugs, as well as scheduling/lifestyle interference. Nevertheless, the most frequently 
reported reasons for non-adherence on the questionnaire were common reasons in both arms, 
such as forgetting/lack of support, and running out of drug. 
 In summary, children frequently experience treatment disruptions to ART, but time to 
treatment disruption was similar for initial PI- and NNRTI-based ART. Although PI regimens 
appear to have greater reported tolerability problems, participants persisted in taking both 
regimens similarly. Initial ART with either a PI or NNRTI may be acceptable for maintaining 
optimal, continuous therapy.  
 A2. Aim 2 Summary of Key Findings 
 In Aim 2, we delved further into the relationship between protocol non-adherence and 
treatment failure. As per Aim 1, we studied treatment-naïve children living with HIV-1 in 
developed countries from the PENPACT-1 trial. We aimed to estimate ITT and per-protocol 
effects of initial PI versus NNRTI-based ART on time to treatment failure, defined as viral or 
clinical failure, by 4 years after randomization. By contrasting the ITT and per-protocol 
estimates, across and within treatment arms, we evaluated the shift in ITT to per-protocol 
estimates for PI regimens versus NNRTI regimens, with the difference in ITT to per-protocol 
estimates defining “robustness” to the nontrivial amounts of non-adherence. 
 
88 
We first performed a modified ITT analysis, as per the definitions of the parent trial. This 
ITT analysis generated an estimate of the effect of ART regimen on time to treatment failure in a 
setting permissive of protocol non-adherence.  
Then, we performed a per-protocol estimate by applying the RF-IPCW method. In 
contrast to the definitions of any treatment disruptions in Aim 1, we defined only treatment 
disruptions that were not medically indicated as protocol deviations. By differentiating between 
medically indicated treatment disruptions and non-medically indicated disruptions, we allowed 
for stops or changes in therapy for adverse events or other appropriate care. Dropout was also 
defined as a protocol deviation. Once a participant experienced a non-medically indicated 
treatment disruption or dropout, the participant was administratively right censored. To account 
for informative censoring, we constructed IPCW based on time-fixed and time-varying 
covariates to upweight similar participants remaining on study. This per-protocol analysis 
generated an estimate of the effect of ART regimen on time to treatment failure in the setting of 
ideal protocol adherence. 
Time to treatment failure was estimated using the complement of the Kaplan-Meier 
estimator and Cox proportional hazards models. IPCW were estimated using pooled logistic 
regression models and stabilized using weeks since randomization. 
We estimated the ITT parameter, the risk of protocol deviations, and the per-protocol 
parameter. As per the parent trial, the ITT estimate had a risk difference of 1.8% with a hazard 
ratio close to the null. Although protocol deviations were common, they were non-differential by 
PI vs. NNRTI treatment arm. In the per-protocol analysis, the 4-year risk differences expanded to 
6.4% unadjusted and 8.9% adjusted, with greater hazard ratios favoring NNRTI-based regimens, 
albeit imprecise. Notably, the shifts in ITT to per-protocol estimates were smaller for PIs (~6%) 
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than for NNRTIs (~10%), consistent with PIs being more robust against protocol non-adherence. 
In summary, in a setting permissive of protocol non-adherence, initial PI vs. NNRTI-
based ART had similar time to treatment failure. However, in a setting of ideal protocol 
adherence, NNRTI-based ART appear to have better point estimates for treatment efficacy. The 
lack of differences in protocol deviations do not support protocol adherence as a differential 
driver of treatment failure. Instead, the greater regimen potency for NNRTIs and the greater 
robustness of PIs against protocol non-adherence appear to be drivers of cancelation effect, 
resulting in the null effect observed in the ITT analysis.  
B. Strengths 
The strengths of this work lie in the structure of the data, the causal inference methods 
applied, and the bridge created by linking randomized clinical data to observational data analysis 
using a principled approach.  
This project used data from the PENPACT-1 trial, the first randomized clinical trial in 
children comparing with two different classes of ART.45 By analyzing these data, we have 
generated one of the first randomized comparisons of pediatric adherence to specific ART 
classes. These data also followed participants longitudinally for an extended follow-up period 
until 4 years after the last enrollee and up to 6.5 years for some participants. This duration of 
follow-up, along with the broad study population base on three continents in 13 countries at 68 
sites across two pediatric HIV networks, stood as one of the largest and richest datasets of its 
time.  
Inherent within the design of this randomized clinical trial was the fulfillment of many 
criteria for causal identification.144,145 Randomization ensured exchangeability of the treatment 
groups, conditional on the randomized stratification variables. Further the data structure 
supported positivity in both aims. In Aim 1, assessment of treatment disruption across 
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randomized arms ensured positivity, as all analyses were performed across measured strata of 
treatment arm, stratification variables, and outcome measurements. In Aim 2, we identified no 
inflation of IPCW to suggest any positivity violations. Finally, the randomized structure allowed 
general consistency in contrasts of PI vs. NNRTI ART classes, but the heterogeneity of specific 
drug choices within classes may have compromised the assumption of treatment invariance, 
which is discussed further in the limitations below. 
While the data structure supported claims to causal inference for ITT analyses, the 
structure of the trial data also lent naturally to observational data analysis of post-randomization 
factors.64 In Aim 2, our focus was on the influence of post-randomization factors of protocol 
deviations, primarily related to non-medically indicated treatment disruptions and dropout. 
Because the initial treatment intervention was randomized with longitudinal follow-up, our per-
protocol analysis could better isolate influences of these post-randomization factors. In other 
words, our analysis leveraged the trial’s randomized design to allow valid examination of post-
randomization effects through causal inference methods. 
 The strengths of the methodology may be illustrated by comparisons to other per-protocol 
analysis approaches.64 In a traditional per-protocol analysis, the analyst determines which 
participants experienced a protocol deviation, excludes such participants, and performs the 
analysis with only the participants who remained adherent to the protocol until the study’s 
primary end point. Traditional per-protocol methods introduce problems, including limiting 
sample size and failing to account for post-randomization informative censoring. For traditional 
per-protocol estimates to generate unbiased estimates, one must assume that participants who 
underwent protocol deviations were similar to participants who remained adherent to the 
protocol, namely that right-censoring is non-informative. This is an unduly strong assumption. 
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Indeed, the very fact that some participants underwent protocol deviations while others did not 
stands as evidence that this assumption is likely untrue and thereby jeopardizes exchangeability 
of these groups. In addition, the exclusion of participants who remained adherent to the protocol 
limits the sample size and discards information available about participants before the protocol 
deviation. This exclusion of data also hampers the per-protocol parameter’s precision. Thus, the 
traditional per-protocol approach tends to bias estimates of both the per-protocol parameter and 
its variance. 
 Our Aim 2 analysis estimated the per-protocol effect by using the RF-IPCW.95 Similar to 
a traditional per-protocol analysis, this approach detects protocol deviations and drops data. In 
contrast to traditional per-protocol analysis, the RF-IPCW approach does not drop all data from a 
participant experiencing a protocol deviation but only right-censors at the time when the protocol 
deviation is detected. Then, by using modeling to approximate conditional exchangeability 
between censored participants and similar remaining participants, IPCW upweights the similar 
remaining participants to compensate for informative censoring. Applying stabilized weights 
helps restore a similar original sample size, thereby maintaining a closer approximation to the 
original sample size and retaining precision. This approach removes the bias due to informative 
censoring if a correct set of time-varying covariates is accounted for, but the extra variability 
added by the estimated weights further reduces precision (in exchange for the possible bias 
reduction). 
 Another per-protocol approach that bears similarity to RF-IPCW directs clinical trial 
enrollment and analytical decisions on participant evaluability. In this approach, study 
participants are assessed during the trial for meeting certain procedural milestones, such as 
remaining adherent to the prescribed regimen and continuing follow-up evaluations until a pre-
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specified trial time point. If not all procedural milestones are met, then this participant and her 
data may be removed from the trial. Then other potential enrollees would be screened, and if 
eligible, another participant would be enrolled to replace the removed participant. Although 
similar in concept, the RF-IPCW method provides better compensation for informative 
censoring, as upweighting a sub-population of similar remaining participants better approximates 
the outcome of the removed participant than a single random replacement, and obviates the 
potential pragmatic, safety, and cost concerns of the replacement method. Thus, RF-IPCW may 
provide a more valid and pragmatic method for informative censoring correction than even real-
time replacement methods. 
C. Limitations 
The principal scientific question of the parent study was to investigate the viral effects of 
initial classes, namely PI vs. NNRTIs. This strategy has been rather unique among pediatric 
RCTs as a class-wide comparison of initial regimens with allowances for switching regimens 
when clinically indicated. As a result, the principal comparisons include heterogeneity among 
specific drugs within classes and switching the initial regimens based on two different pre-
specified viral criteria. The most relevant comparative pediatric trials contrasted specific drugs in 
each class, usually LPV/r versus nevirapine with or without specification of accompanying NRTI 
backbones and without the same freedom to switch drugs for the same viral outcome. These 
trials had mixed results, with one major trial supporting PENPACT-1 trial results and another 
with strong superiority of LPV/r over nevirapine.100,121 These trials differed in study populations 
from PENPACT-1, as most participants in those trials were younger, possibly sicker, and in 
developing countries, but a major difference was in their homogeneity of treatment contrasts. 
PENPACT-1 had more heterogeneity of regimens with unboosted and boosted PIs, nevirapine or 
efavirenz for the NNRTI, and heterogeneity in the NRTI backbone. Although PENPACT-1 was 
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intended to evaluate ART classes, variability of specific drug choices may compromise the 
assumption of treatment invariance. 
Another major limitation was measurement error. First, we had no direct measures of 
drug exposure, such as therapeutic drug monitoring. Treatment records captured only prescribing 
events and documented ART disruptions, and the adherence questionnaires relied on accurate 
reporting by either the child or the caregiver, if present and willing to answer. Although we 
relied on a questionnaire that has previously been validated,61 reporting biases and unanswered 
questionnaires may have affected our measures of missed doses. Direct measurements of drug 
concentrations in plasma, peripheral blood mononuclear cells, hair, or urine would have been 
preferable.141-143 Second, adherence questionnaires in this study focused on ART adherence over 
the 3 days prior to the most recent visit and inquired about adherence barriers encountered over 
the prior 2 weeks, rather than a daily measure of adherence throughout the study. The time-
varying nature of treatment disruption means that patients may have experienced an initial or 
temporary period of treatment disruption that was subsequently corrected, but our analysis 
presents only data on time to first event of treatment disruption. Of note, most treatment failures 
occurred early in the study, most frequently by week 24. PENPACT-1 adherence questionnaires 
did not start until the week 24 visit, and viral failure events were only defined starting at week 
24; although at 24 weeks, treatment disruptions between 0 and 24 weeks were recorded. Third, 
limited participant report of individual drugs missed on the adherence questionnaire precluded 
definitive identification of treatment disruptions of individual drugs. Instead, we assessed 
treatment disruption to any component of the ART regimen. Fourth, heterogeneity of adherence 
questionnaires across networks, ages, and respondents regarding barriers to therapy should 
caution against rigorous interpretation of reasons for treatment disruptions. 
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In our interpretation of the potential drivers of the cancelation effect, we must recognize 
that other explanations of the data are plausible. An alternative explanation of our observed ITT 
to per-protocol shift may be that participants on PIs experienced more medically indicated 
treatment disruptions that led to viral failure. Our method only censored and corrected for non-
medically indicated treatment disruptions and dropouts, as medically indicated treatment 
disruptions, such as adverse events or pregnancy on a regimen with potential teratogenicity, 
would have been appropriate medical care. If PIs and NNRTIs led to differential medically 
indicated treatment switches or stoppages, which then led to differential treatment failure, such 
would also have led to a separation of treatment failure curves. However, additional analysis of 
treatment disruptions in the PENPACT-1 data indicated that although PIs may be more difficult 
to tolerate, the most frequent reasons documented for treatment disruptions were events common 
to the classes, such as forgetting to take the medications, and overall treatment disruptions were 
comparable across PI and NNRTI arms. 
Finally, this study size limited the precision of our estimates. In Aim 1, the size was not 
sufficient to distinguish differences on the order of 7%, as was seen at 4 years. In Aim 2, 
confidence intervals were wide relative to the effect estimates, despite clinically meaningful 
shifts in ITT to per-protocol effect estimates. 
D. Public Health Significance and Conclusion 
 The major insights from our project relate to subject matter, methodology, and a new 
understanding of the potential components driving observed treatment efficacy. 
 Regarding subject matter, we conclude that NNRTIs may not be inferior initial ART for 
children in developed countries, particularly in a setting of low NNRTI resistance and expected 
good adherence to ART. Based on another clinical trial finding superiority of LPV/r over 
nevirapine-based ART in children <3 years old in developing countries, the WHO has favored 
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LPV/r as initial therapy for children under 3 years old.84,100,146 Resistance to NNRTIs has also 
been increasing in developing countries, where nevirapine is still commonly used for prevention 
of mother-to-child transmission.147 In our PENPACT-1 analyses, time to treatment disruption 
and time to treatment failure were comparable for NNRTIs and PIs in settings permissive of 
protocol non-adherence. In a setting of ideal protocol adherence, point estimates favored initial 
NNRTI-based ART. Since the PENPACT-1 protocol screened for baseline resistance as part of 
eligibility criteria, our study population had low levels of resistance. In this setting, the US 
DHHS guidelines for pediatric ART continue to prefer initial ART with two NRTIs and either a 
PI, NNRTI, or INSTI.101 We suggest that for children in developing countries without baseline 
NNRTI resistance, initial NNRTI-based ART remains a viable option, especially if adherence 
may be ensured.   
 Methodologically, we have demonstrated the flexibility and utility of the RF-IPCW 
approach as applied to a pediatric HIV clinical trial. To our knowledge, we are the first to 
highlight the shift in risk of outcomes within a treatment across the ITT and per-protocol 
parameters. Highlighting this within-treatment arm difference may be helpful in understanding 
the effects of treatment, protocol adherence, and robustness to protocol non-adherence. Post-
randomization effects, particularly non-adherence, remain major determinants of HIV outcomes 
and may be influential on ITT outcomes.64,95 RF-IPCW have not yet seen demonstrable uptake in 
pediatric HIV clinical trials.84 In this case, RF-IPCW revealed insights into the relationships 
among treatment regimen, protocol non-adherence, regimen potency, and regimen robustness in 
contributing to observed treatment efficacy. Our results disproved our own hypothesis that 
regimen-specific non-adherence was a major component of the observed cancelation effect, and 
the drivers of the observed null effect were only identified by examining effects through the RF-
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IPCW method.  
 Finally, we conclude that a new framework for understanding the components of 
treatment efficacy may be needed. Rather than non-adherence canceling the efficacy of the 
treatment regimens, as we had hypothesized, regimen potency and robustness canceled. Instead 
of focusing on the direct effects of non-adherence on treatment outcomes, perhaps we should 
conceptualize regimen potency versus robustness. Throughout this project, we conflated both 
these concepts into one concept of “treatment efficacy”. Some adult adherence literature has 
already delineated some aspects of treatment goals. For example, a study in adults evaluated 
whether ART regimens require different adherence thresholds for viral suppression versus 
avoidance of antiretroviral resistance.54 We submit that the literature may not have gone far 
enough. Most publications do not explicitly separate out regimen potency and robustness as 
components of treatment efficacy. In our analysis of PENPACT-1, regimen potency and 
robustness were opposing effects and canceled sufficiently to yield a null effect estimate in the 
ITT analysis. However, these effects may not always oppose, nor may their magnitudes always 
be similar enough to cancel. We conclude that considering regimen potency and regimen 
robustness, in addition to traditional components (e.g., adherence), would provide a more 





APPENDIX 1: ADDITIONAL BACKGROUND ON ADHERENCE IN HIV-INFECTED 
CHILDREN 
A. Challenges to Pediatric ART Adherence 
Pediatric adherence is a challenge. Adherence challenges are accentuated in pediatric 
populations,22-25 as pediatric adherence is directly related to the overall health and psychosocial 
factors of the entire family. Poverty and low caregiver education, along with the resultant 
shortages in nutrition and transportation, have been associated with worse adherence in 
children.19,42,47,49,50,76,148 In addition, health and financial strains may impact adherence by 
weakening the caregiver-child relationship.76 At the extreme, many children are left as orphans, 
who are especially prone to poor adherence.42,149 While some children are more adherent under 
the care of foster parents than biological parents,44 altered support systems add their own 
complexities. Impaired care support structures highlight pediatric adherence struggles. 
Unique to pediatric adherence are the rapid transitions across ages. Although published 
literature has not been consistent regarding age-related effects for younger children,43,44 the 
dependency and needs of pediatric patients differ widely as they grow from infancy to 
adolescence.22-25 Adherence concerns move from simple child refusal when younger20 to lack of 
commitment when adolescents.24 As age increases, fear of stigma also shifts from being an 
exclusive parental concern to becoming a peer-pressure driven individual concern. Stigma can 
strongly influence adherence, although the direction of the influence may be in either 
direction.47,49,150 Nevertheless, an overarching age-dependent adherence consideration is degree 
of supervision.20,76 Caregiver factors may explain why some studies conflict with prior data on 
adherence effects of income and degree of childhood illness.44,77 Finally, age-dependent factors 
must also consider treatment fatigue.42,47 Supporting adherence from earlier ages or through 
difficult periods may become progressively more difficult over time, and lifelong treatment is 
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longer in children than in adults. With unique challenges in pediatric populations, one must 
identify factors that are modifiable and sustainable. 
B. Potentially Modifiable Risk Factors for Poor Adherence to ART in HIV-Infected 
Children 
Some reasons for poor adherence relate to simple issues of daily life (Table S1). 
Adherence questionnaires find that reasons for missing doses include child refusal20 and 
forgetting.76 Daily routine appears to play a role, as disruptions of routine or scheduling issues 
are reported adherence barriers.20,77   
Many families fear disclosure of HIV status to their children, thereby precluding 
children’s involvement in their own care.20,50,71,151 Lack of disclosure has been consistently 
associated with worse adherence.24,49,77,148,151-153 Disclosure also has benefits for mental health, 
psychosocial development, caregiver well-being, and future planning,152 while not being 
associated with emotional trauma or divulging to others.153 Children who know their HIV status 
have less frustration, less conflict in the child-caregiver relationship, and less conflict about 
medications.76 However, caregivers struggle with acceptance of the HIV diagnosis themselves 
and fears of disclosure.154 Thus, disclosure is a major adherence issue that should be addressed at 
the caregiver level. 
Optimal pediatric adherence depends on caregiver involvement. Caregiver supervision is 
critical,20,76 and caregiver mental health—especially substance abuse and depression—plays a 
major role in pediatric adherence.47,50,87 Caregiver substance abuse is commonly identified as an 
adherence challenge.50,87 Depression is also common and negatively impacts ART adherence,47 
particularly in the postpartum period.155 Indeed, a caregiver’s well-being is affected by the HIV 
diagnosis.154 Support for caregivers can benefit not only the caregiver, but also the child’s 
adherence.71,76 Thus, services directed at caregivers may optimize pediatric care. 
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Mental health challenges in children also are a major barrier to antiretroviral adherence. 
HIV-infected children in particular suffer from psychiatric diagnoses, such as depression, 
anxiety, disruptive disorders, hyperactive disorders, and post-traumatic stress disorder156-158—
which require more intensive psychiatric interventions.     
To date, most pediatric adherence interventions have focused on social and behavioral 
interventions.159 At the level of the individual child, children who have received education about 
ART,24 pill swallowing training,89 or disclosure of HIV status have had better 
adherence.24,49,77,148,151-153 Tools such as use of pill carriers may be beneficial,24 but medication 
reminders have had mixed results.41,49 At the caregiver level, adherence education and 
counseling have been associated with better adherence.49,87,160 Home-based therapy also yields 
improvements.41,160-163 
However, little research has been published on physician-level decisions about treatment 




Table S1. Potentially modifiable risk factors for poor pediatric adherence. 
Risk Factors 
Dysfunctional Family System: 
• Forgetfulness 
• Medication refusal 
• Disrupted household routine 
• Lack of child supervision 
• Lack of support for caregiver 
Lack of disclosure of HIV status to child 
























































APPENDIX 4: SUPPLEMENTAL FIGURES 









Figure S.2. Causal diagram conceptualizing the relationship among antiretroviral therapy 
(ART) regimen assigned, adherence, and HIV viral load at multiple time points. This 
diagram is simplified to illustrate relationships. Adherence to ART is a category of ART 
received. Protocol non-adherence is defined as a discordance between ART assigned and ART 
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